

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	126	564/32	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2007/07/04 19:16
S2	76	564/61	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2007/07/03 15:23
S3	596	514/886	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2007/07/03 15:23
S4	10	S1 and S2	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2007/07/03 15:26
S5	0	S4 and S3	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2007/07/03 15:23
S6	1043378	tetrahydro naphthalene derivatives	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2007/07/03 15:26
S7	387	S3 and S6	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2007/07/03 15:26
S8	1627829	alkyl substituted ureas	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2007/12/04 08:13
S9	51990	aryl substituted ureas	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2007/12/04 08:13
S10	51990	S8 and S9	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2007/12/04 08:14
S11	1238094	comparison	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2007/12/04 08:14
S12	17658	S10 and S11	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2007/12/04 08:14

EAST Search History

S13	188268	Biological studies	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2007/12/04 08:14
S14	5758	S12 and S13	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2007/12/04 08:14
S15	9812	structure-activity relationship	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2007/12/04 08:14
S16	730	S14 and S15	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2007/12/04 08:34
S17	51121	alkyl aryl substituted ureas	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2007/12/04 09:46
S18	1609	S15 and S17	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2007/12/04 08:35
S19	1219	S13 and S18	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2007/12/04 08:35
S20	9057	tetrahydronaphthalene	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2007/12/04 08:36
S21	76	S18 and S20	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2007/12/04 08:36
S22	9057	tetrahydronaphthalene	US-PGPUB; USPAT; EPO; DERWENT	WITH	ON	2007/12/04 09:46
S23	0	aralyalkyl ureas	US-PGPUB; USPAT; EPO; DERWENT	WITH	ON	2007/12/04 09:46
S24	0	S22 and S23	US-PGPUB; USPAT; EPO; DERWENT	WITH	ON	2007/12/04 09:47
S25	554	arylalkyl ureas	US-PGPUB; USPAT; EPO; DERWENT	WITH	ON	2007/12/04 09:47

EAST Search History

S26	8	S22 and S25	US-PGPUB; USPAT; EPO; DERWENT	WITH	ON	2007/12/04 09:52
S27	30142	urea derivative	US-PGPUB; USPAT; EPO; DERWENT	WITH	ON	2007/12/04 09:52
S28	12808	urinary incontinence	US-PGPUB; USPAT; EPO; DERWENT	WITH	ON	2007/12/04 09:52
S29	384	S27 and S28	US-PGPUB; USPAT; EPO; DERWENT	WITH	ON	2007/12/04 09:55
S30	36	Nalkyl compounds	US-PGPUB; USPAT; EPO; DERWENT	WITH	ON	2007/12/04 09:55
S31	6	Naryl compounds	US-PGPUB; USPAT; EPO; DERWENT	WITH	ON	2007/12/04 09:56
S32	129863	Biological activity	US-PGPUB; USPAT; EPO; DERWENT	WITH	ON	2007/12/04 09:56
S33	2	S30 and S32	US-PGPUB; USPAT; EPO; DERWENT	WITH	ON	2007/12/04 09:56
S34	0	S23 and S31	US-PGPUB; USPAT; EPO; DERWENT	WITH	ON	2007/12/04 09:56
S35	152	S32 and S25	US-PGPUB; USPAT; EPO; DERWENT	WITH	ON	2007/12/04 10:36
S36	32	"4939149"	US-PGPUB; USPAT; EPO; DERWENT	WITH	ON	2007/12/04 11:19
S37	7	"6476076"	US-PGPUB; USPAT; EPO; DERWENT	WITH	ON	2007/12/04 11:20
S38	127	564/32	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2007/12/06 17:09

EAST Search History

S39	346	514/630	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2007/12/06 17:10
-----	-----	---------	--	----	----	------------------

result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 15:43:25 ON 29 NOV 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 15:43:32 ON 29 NOV 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 NOV 2007 HIGHEST RN 956214-95-2

DICTIONARY FILE UPDATES: 28 NOV 2007 HIGHEST RN 956214-95-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:


<http://www.cas.org/support/stngen/stndoc/properties.html>

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>

Uploading C:\Program Files\Stnexp\Queries\10537482n6.str



chain nodes :

11 12 13 26 27 28

ring nodes :

1 2 3 4 5 6 7 8 9 10 14 15 16 17 18 19 20 21 22 23 24 25
 chain bonds :
 4-11 11-12 12-13 12-28 13-14 18-20 26-27
 ring bonds :
 1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 14-15 14-19 15-16 16-17
 17-18 18-19 20-21 20-25 21-22 22-23 23-24 24-25
 exact/norm bonds :
 2-7 3-10 4-11 7-8 8-9 9-10 11-12 12-13 12-28 13-14 26-27
 exact bonds :
 18-20
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 14-15 14-19 15-16 16-17 17-18 18-19 20-21
 20-25 21-22 22-23 23-24 24-25

Match level :
 1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
 10:CLASS 11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS
 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS
 26:Atom 27:Atom 28:Atom

L1 STRUCTURE UPLOADED


=> que L1

L2 QUE L1

=> d L1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s L1 full

FULL SEARCH INITIATED 15:43:54 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 4973 TO ITERATE

100.0% PROCESSED 4973 ITERATIONS
 SEARCH TIME: 00.00.01

19 ANSWERS

L3 19 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
172.10	172.31

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 15:43:59 ON 29 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Nov 2007 VOL 147 ISS 23
FILE LAST UPDATED: 28 Nov 2007 (20071128/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s L3

L4 5 L3

=> d L4 1-5 bib abs hitstr

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:177881 CAPLUS

DN 142:274025

TI Methods using a combination of a p38 MAP kinase inhibitor with another active agent for the treatment of chronic obstructive pulmonary disease (COPD) and pulmonary hypertension

IN Gupta, Abhya; Iacono, Philippe Didier; Kelash-Cannavo, Linda Jean; Madwed, Jeffrey B.; Park, Jung-Yong; Way, Susan Lynn; Yazdanian, Mehran

PA Boehringer Ingelheim Pharmaceuticals, Inc., USA; Boehringer Ingelheim Pharma GmbH & Co. KG; Boehringer Ingelheim France S.A.S.

SO PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005018624	A2	20050303	WO 2004-US27013	20040819
WO 2005018624	A3	20050506		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,			

SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

AU 2004266719	A1	20050303	AU 2004-266719	20040819
CA 2536293	A1	20050303	CA 2004-2536293	20040819
US 2005148555	A1	20050707	US 2004-921448	20040819
EP 1658060	A2	20060524	EP 2004-781654	20040819
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1838958	A	20060927	CN 2004-80024151	20040819
BR 2004013757	A	20061031	BR 2004-13757	20040819
JP 2007503393	T	20070222	JP 2006-524065	20040819
MX 2006PA01931	A	20060920	MX 2006-PA1931	20060217
IN 2006DN00812	A	20070817	IN 2006-DN812	20060217
KR 2007035466	A	20070330	KR 2006-703583	20060221
PRAI US 2003-497376P	P	20030822		
WO 2004-US27013	W	20040819		
AB	Methods are disclosed for treating COPD and pulmonary hypertension using p38 MAP Kinase inhibitors in combination with one or more other active ingredients.			
IT	847023-73-8 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (p38 MAP kinase inhibitor combination with another active agent for treatment of chronic obstructive pulmonary disease and pulmonary hypertension)			
RN	847023-73-8 CAPLUS			
CN	Urea, N-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]-N'-[6-(pentyloxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)			


PAGE 1-A





L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:515474 CAPLUS
 DN 141:71359
 TI Preparation of tetrahydronaphthalene derivatives as vaniloid receptor antagonists
 IN Tajimi, Masaomi; Kokubo, Toshio; Shiroo, Masahiro; Tsukimi, Yasuhiro; Yura, Takeshi; Urbahns, Klaus; Yamamoto, Noriyuki; Mogi, Muneto; Fujishima, Hiroshi; Masuda, Tsutomu; Yoshida, Nagahiro; Moriwaki, Toshiya
 PA Bayer Healthcare Ag, Germany
 SO PCT Int. Appl., 81 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004052846	A1	20040624	WO 2003-EP13453	20031128
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2508618	A1	20040624	CA 2003-2508618	20031128
	AU 2003294748	A1	20040630	AU 2003-294748	20031128
	EP 1569896	A1	20050907	EP 2003-785688	20031128
	EP 1569896	B1	20070815		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2006509018	T	20060316	JP 2004-557951	20031128
	AT 370118	T	20070915	AT 2003-785688	20031128
	US 2006128704	A1	20060615	US 2005-537482	20051118
PRAI	EP 2002-27523	A	20021206		
	WO 2003-EP13453	W	20031128		
OS	MARPAT 141:71359				
GI					



AB The title compds. I [R1 = H, alkyl; X = biphenyl, etc.] are prepared The tetrahydronaphthalene derivs. of the present invention have excellent activity as VR1 antagonists and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, etc. The bioactivity of I was demonstrated.


IT 711015-39-3P 711015-41-7P 711015-44-0P
711015-51-9P 711015-52-0P 711015-53-1P
711015-62-2P 711015-63-3P 711015-67-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tetrahydronaphthalene derivs. as vaniloid receptor antagonists)


RN 711015-39-3 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)




RN 711015-41-7 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]- (CA INDEX NAME)




RN 711015-44-0 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)




RN 711015-51-9 CAPLUS

CN Urea, N-(3'-methoxy[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-52-0 CAPLUS


CN Urea, N-(4'-methoxy[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-53-1 CAPLUS


CN Urea, N-(2',5'-dimethoxy[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-

hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-62-2 CAPLUS

CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[3'-(trifluoromethoxy) [1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 711015-63-3 CAPLUS

CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[4'-(trifluoromethoxy) [1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 711015-67-7 CAPLUS

CN Urea, N-[4'-[2-(4-morpholinyl)ethoxy][1,1'-biphenyl]-3-yl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:453169 CAPLUS

DN 141:7439

TI Preparation of amino acids derivatives containing biphenyl unit as activators, in particular as agonists of PPAR γ receptors, and their use in cosmetic or pharmaceutical compositions

IN Clary, Laurence; Bouix-Peter, Claire; Rivier, Michel; Collette, Pascal; Jomard, Andre

PA Galderma Research & Development, S.N.C., Fr.

SO PCT Int. Appl., 114 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2004046091	A2	20040603	WO 2003-EP14861	20031118	
	WO 2004046091	A3	20040729			
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:			BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	FR 2847251	A1	20040521	FR 2002-14465	20021119	
	FR 2847251	B1	20061117			
	CA 2505299	A1	20040603	CA 2003-2505299	20031118	
	AU 2003290120	A1	20040615	AU 2003-290120	20031118	
	BR 2003014898	A	20050802	BR 2003-14898	20031118	
	EP 1575911	A2	20050921	EP 2003-782482	20031118	
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK		
	JP 2006506446	T	20060223	JP 2004-570287	20031118	
	US 2005256116	A1	20051117	US 2005-131302	20050518	
PRAI	FR 2002-14465	A	20021119			
	US 2003-454310P	P	20030314			
	WO 2003-EP14861	W	20031118			
OS	MARPAT 141:7439					
GI						

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein R1 = (un)substituted Ph, R6C:CHR5, Fmoc, BOC, benzyl, and trifluoromethyl N-protected α -amino acids, etc.; R2 = (un)substituted oxadiazole, C(:O)R9, (un)substituted 5-membered heterocyclyl containing O, N, and/or S; R3 = H, halo, alkyl, OH and derivs., NO2, NH2 and derivs., etc.; R4 = aryl/alkyl, hetero/aryl, heterocyclyl, 9-fluorenylmethyl; R5 = H, ar/alkyl, hetero/aryl, heterocyclyl, etc.; R6 = H, alkyl; R9 = OH and derivs., hetero/aryl, aralkyl, heterocyclyl, NH2 and derivs., etc.; A = (CH2)z-(NR13)y-(CO)x-(D)w-; D = O, S, NH and derivs., CH2; x, y, z = independently 0 or 1; w = 0-6; R15 = H, C1-7 alkyl; their optical and geometrical isomers, and their salts] were prepared as PPAR γ agonists. I are useful in human or veterinary medicine (in dermatol., as well as in the field of cardiovascular diseases, immune diseases and/or diseases related to lipid metabolism), or in cosmetic compns. For example, II was prepared, in 98% yield, by acylation of dibenzylamine with (S)-2-(2-Benzoylphenylamino)-3-[3'-(3-heptyl-1-methylureido)-1,1'-biphenyl-4-yl]propionic acid (preparation given). II displayed an apparent Kd = 8 nM. I showed selective affinity for PPAR γ receptors, compared to PPAR α and PPAR β receptors.


IT 692258-91-6P, (S)-2-(2-Benzoylphenylamino)-3-[3'-(1-methyl-3-(naphthalen-1-yl)ureido)-1,1'-biphenyl-4-yl]propionic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PPAR γ agonist; preparation of amino acids derivs. containing biphenyl unit as agonists of PPAR γ receptors and their use in cosmetic or pharmaceutical compns.)

RN 692258-91-6 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, α -[(2-benzoylphenyl)amino]-3'-[methyl[(1-naphthalenylamino)carbonyl]amino]-, (α S)- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:411319 CAPLUS

DN 140:423945

TI Preparation of amino acids derivatives containing biphenyl unit as activators, in particular as agonists of PPAR γ receptors, and their use in cosmetic or pharmaceutical compositions

IN Clary, Laurence; Bouix, Peter Claire; Rivier, Michel; Collette, Pascal; Jomard, Andre

PA Galderma Research & Development, Fr.

SO Fr. Demande, 65 pp.

CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2847251	A1	20040521	FR 2002-14465	20021119
	FR 2847251	B1	20061117		
	CA 2505299	A1	20040603	CA 2003-2505299	20031118
	WO 2004046091	A2	20040603	WO 2003-EP14861	20031118
	WO 2004046091	A3	20040729		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003290120	A1	20040615	AU 2003-290120	20031118
	BR 2003014898	A	20050802	BR 2003-14898	20031118
	EP 1575911	A2	20050921	EP 2003-782482	20031118
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1711239	A	20051221	CN 2003-80103336	20031118
	JP 2006506446	T	20060223	JP 2004-570287	20031118
	US 2005256116	A1	20051117	US 2005-131302	20050518
	ZA 2005004205	A	20060222	ZA 2005-4205	20050524
PRAI	FR 2002-14465	A	20021119		
	US 2003-454310P	P	20030314		
	WO 2003-EP14861	W	20031118		
OS	MARPAT 140:423945				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein R1 = (un)substituted Ph, R6C:CHR5, Fmoc, BOC, benzyl, and trifluoromethyl N-protected α -amino acids, etc.; R2 = (un)substituted oxadiazole, C(:O)R9, (un)substituted 5-membered heterocyclyl containing O, N, and/or S; R3 = H, halo, alkyl, OH and derivs., NO₂, NH₂ and derivs., etc.; R4 = aryl/alkyl, hetero/aryl, heterocyclyl, 9-fluorenylmethyl; R5 = H, ar/alkyl, hetero/aryl, heterocyclyl, etc.; R6 = H, alkyl; R9 = OH and derivs., hetero/aryl, aralkyl, heterocyclyl, NH₂ and derivs., etc.; A = (CH₂)_z-(NR₁₃)_y-(CO)_x-(D)_w; D = O, S, NH and derivs., CH₂; x, y, z = independently 0 or 1; w = 0-6; their optical and geometrical isomers, and their salts] were prepared as PPAR γ agonists. I are useful in human or veterinary medicine (in dermatol., as well as in the field of cardiovascular diseases, immune diseases and/or diseases related to lipid metabolism), or in cosmetic compns. For example, II was prepared, in 98% yield, by acylation of dibenzylamine with (S)-2-(2-Benzoylphenylamino)-3-[3'-(3-heptyl-1-methylureido)-1,1'-biphenyl-4-yl]propionic acid (preparation given). II displayed an apparent K_d = 8 nM. I showed selective affinity for PPAR γ receptors, compared to PPAR α and PPAR β receptors.


IT 692258-91-6P, (S)-2-(2-Benzoylphenylamino)-3-[3'-(1-methyl-3-(naphthalen-1-yl)ureido)-1,1'-biphenyl-4-yl]propionic acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PPAR γ agonist; preparation of amino acids derivs. containing biphenyl unit as agonists of PPAR γ receptors and their use in cosmetic or pharmaceutical compns.)

RN 692258-91-6 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, α -[(2-benzoylphenyl)amino]-3'-[methyl[(1-naphthalenylamino)carbonyl]amino]-, (α S)- (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:133223 CAPLUS
DN 138:169972
TI Preparation of substituted N-naphthyl-N'-phenylureas and N-substituted naphthylacetamides as vanilloid receptor 1 (VR1) antagonists
IN Yura, Takeshi; Mogi, Munet; Ikegami, Yuka; Masuda, Tsutoma; Kokubo, Toshio; Urbahns, Klaus; Lowinger, Timothy B.; Yoshida, Nagahiro; Freitag, Joachim; Meier, Heinrich; Wittka-Nopper, Reilinde; Marumo, Makiko; Shiroo, Masahiro; Tajimi, Masaomi; Takeshita, Keisuke; Moriwaki, Toshuda; Tsukimi, Yasuhiro
PA Bayer AG, Germany
SO PCT Int. Appl., 186 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003014064	A1	20030220	WO 2002-EP8493	20020731
	WO 2003014064	A8	20031127		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	JP 2003055209	A	20030226	JP 2001-232503	20010731
	CA 2455754	A1	20030220	CA 2002-2455754	20020731
	AU 2002325381	A1	20030224	AU 2002-325381	20020731
	EP 1414788	A1	20040506	EP 2002-758413	20020731
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
	JP 2005501873	T	20050120	JP 2003-524319	20020731
	US 2004259875	A1	20041223	US 2004-485481	20040726
PRAI	JP 2001-232503	A	20010731		
	JP 2001-392310	A	20011225		
	WO 2002-EP8493	W	20020731		
OS	MARPAT 138:169972				
GI					



AB The title compds. R7Q(Y)C(O)N XR6 [X = (un)substituted Ph, cycloalkyl optionally fused by benzene, thienyl, quinolyl, etc.; Q = CH, N; R6, R7 = H, Me; Y = substituted 1-naphthyl] or their salts which have vanilloid receptor 1 (VR1) antagonistic activity, and therefore are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischemia, neurodegeneration, stroke, incontinence and/or inflammatory disorders, were prepared Thus, reacting 8-amino-5,7-dichloro-2-naphthol (preparation given)

with 3-chlorophenyl isocyanate in 1,4-dioxane afforded 39% I which showed IC50 of ≤ 10 nM for VR1.


IT 497150-15-9P 497150-16-0P 497150-17-1P
497150-18-2P 497150-19-3P 497150-42-2P
497150-47-7P 497150-54-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted N-naphthyl-N'-phenylureas and N-substituted naphthylacetamides as vanilloid receptor 1 (VR1) antagonists)


RN 497150-15-9 CAPLUS

CN Urea, N-[7-(acetyloxy)-2,4-dichloro-1-naphthalenyl]-N'-(2'-chloro[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 497150-16-0 CAPLUS

CN Urea, N-[7-(acetyloxy)-2,4-dibromo-1-naphthalenyl]-N'-[1,1'-biphenyl]-3-yl-
(CA INDEX NAME)




RN 497150-17-1 CAPLUS

CN Urea, N-[7-(acetyloxy)-2,4-dichloro-1-naphthalenyl]-N'-(3'-methoxy[1,1'-
biphenyl]-3-yl)- (CA INDEX NAME)




RN 497150-18-2 CAPLUS

CN Urea, N-[7-(acetyloxy)-2,4-dichloro-1-naphthalenyl]-N'-(3'-chloro-4'-
methyl[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 497150-19-3 CAPLUS

CN Urea, N-[7-(acetyloxy)-2,4-dichloro-1-naphthalenyl]-N'-(4'-chloro-3'-fluoro[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 497150-42-2 CAPLUS


CN Urea, N-(2,4-dichloro-7-hydroxy-1-naphthalenyl)-N'-(3'-methoxy[1,1'-biphenyl]-3-yl)-, monopotassium salt (9CI) (CA INDEX NAME)



● K


RN 497150-47-7 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-[[[(2,4-dichloro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]- (CA INDEX NAME)



RN 497150-54-6 CAPLUS

CN Urea, N-(2,4-dichloro-7-hydroxy-1-naphthalenyl)-N'-(3'-methoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	26.82	199.13
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.90	-3.90

STN INTERNATIONAL LOGOFF AT 15:44:25 ON 29 NOV 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptalxn1621

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JUL 02 LMEDLINE coverage updated
NEWS 3 JUL 02 SCISEARCH enhanced with complete author names
NEWS 4 JUL 02 CHEMCATS accession numbers revised
NEWS 5 JUL 02 CA/CAPplus enhanced with utility model patents from China
NEWS 6 JUL 16 CAPplus enhanced with French and German abstracts
NEWS 7 JUL 18 CA/CAPplus patent coverage enhanced
NEWS 8 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9 JUL 30 USGENE now available on STN
NEWS 10 AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 11 AUG 06 FSTA enhanced with new thesaurus edition
NEWS 12 AUG 13 CA/CAPplus enhanced with additional kind codes for granted patents
NEWS 13 AUG 20 CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS 14 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 15 AUG 27 USPATOLD now available on STN
NEWS 16 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 17 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 18 SEP 13 FORIS renamed to SOFIS
NEWS 19 SEP 13 INPADOCDB enhanced with monthly SDI frequency
NEWS 20 SEP 17 CA/CAPplus enhanced with printed CA page images from 1967-1998
NEWS 21 SEP 17 CAPplus coverage extended to include traditional medicine patents
NEWS 22 SEP 24 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 23 OCT 02 CA/CAPplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 24 OCT 19 BEILSTEIN updated with new compounds
NEWS 25 NOV 15 Derwent Indian patent publication number format enhanced
NEWS 26 NOV 19 WPIX enhanced with XML display format
NEWS 27 NOV 30 ICSD reloaded with enhancements
NEWS 28 DEC 04 LINPADOCDB now available on STN

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 14:39:36 ON 04 DEC 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 14:39:51 ON 04 DEC 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 DEC 2007 HIGHEST RN 956575-10-3

DICTIONARY FILE UPDATES: 3 DEC 2007 HIGHEST RN 956575-10-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:


<http://www.cas.org/support/stngen/stdoc/properties.html>

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>

Uploading C:\Program Files\Stnexp\Queries\10537482 species.str



chain nodes :

11 12 13 26 27 28 29 30 31 32

```

ring nodes :
1  2  3  4  5  6  7  8  9  10  14  15  16  17  18  19  20  21  22  23  24  25
chain bonds :
4-11  9-31  11-12  12-13  12-30  13-14  18-20  23-26  26-27  26-28  26-29  31-32
ring bonds :
1-2  1-6  2-3  2-7  3-4  3-10  4-5  5-6  7-8  8-9  9-10  14-15  14-19  15-16  16-17
17-18  18-19  20-21  20-25  21-22  22-23  23-24  24-25
exact/norm bonds :
2-7  3-10  4-11  7-8  8-9  9-10  9-31  11-12  12-13  12-30  13-14
exact bonds :
18-20  23-26  26-27  26-28  26-29  31-32
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  14-15  14-19  15-16  16-17  17-18  18-19  20-21
20-25  21-22  22-23  23-24  24-25

```

```

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS
26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom

```

L1 STRUCTURE UPLOADED


=> que L1

L2 QUE L1

=> d L1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s L1 full

FULL SEARCH INITIATED 14:40:16 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 512 TO ITERATE

100.0% PROCESSED 512 ITERATIONS
SEARCH TIME: 00.00.01

1 ANSWERS

L3 1 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 14:40:22 ON 04 DEC 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Dec 2007 VOL 147 ISS 24

FILE LAST UPDATED: 3 Dec 2007 (20071203/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s L3

L4 1 L3

=> d L4 bib abs hitstr

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:515474 CAPLUS

DN 141:71359

TI Preparation of tetrahydronaphthalene derivatives as vaniloid receptor antagonists

IN Tajimi, Masaomi; Kokubo, Toshio; Shiroo, Masahiro; Tsukimi, Yasuhiro; Yura, Takeshi; Urbahns, Klaus; Yamamoto, Noriyuki; Mogi, Muneto; Fujishima, Hiroshi; Masuda, Tsutomu; Yoshida, Nagahiro; Moriwaki, Toshiya

PA Bayer Healthcare Ag, Germany

SO PCT Int. Appl., 81 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004052846	A1	20040624	WO 2003-EP13453	20031128
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,			

TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2508618	A1	20040624	CA 2003-2508618	20031128
AU 2003294748	A1	20040630	AU 2003-294748	20031128
EP 1569896	A1	20050907	EP 2003-785688	20031128
EP 1569896	B1	20070815		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006509018	T	20060316	JP 2004-557951	20031128
AT 370118	T	20070915	AT 2003-785688	20031128
US 2006128704	A1	20060615	US 2005-537482	20051118
PRAI EP 2002-27523	A	20021206		
WO 2003-EP13453	W	20031128		
OS MARPAT 141:71359				
GI				



AB The title compds. I [R1 = H, alkyl; X = biphenyl, etc.] are prepared The tetrahydronaphthalene derivs. of the present invention have excellent activity as VR1 antagonists and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, etc. The bioactivity of I was demonstrated.


IT 711015-45-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tetrahydronaphthalene derivs. as vaniloid receptor antagonists)

RN 711015-45-1 CAPLUS


CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



=> FIL STNGUIDE
COST IN U.S. DOLLARS

SINCE FILE

TOTAL



N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[4'(methylthio)-biphenyl-3-yl]urea

L2 STRUCTURE UPLOADED


=> que L2 AND L1

L3 QUE L2 AND L1

=> d L2

L2 HAS NO ANSWERS

L2 STR



G1 Ak,H

Structure attributes must be viewed using STN Express query preparation.

=> s L2 full

FULL SEARCH INITIATED 09:19:09 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 4830 TO ITERATE

100.0% PROCESSED 4830 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

L4 3 SEA SSS FUL L2

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 09:19:14 ON 07 DEC 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Dec 2007 VOL 147 ISS 25

FILE LAST UPDATED: 6 Dec 2007 (20071206/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>


=> s L4

L5 1 L4

=> d L5 bib abs hitstr

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:515474 CAPLUS
DN 141:71359
TI Preparation of tetrahydronaphthalene derivatives as vaniloid receptor antagonists
IN Tajimi, Masaomi; Kokubo, Toshio; Shiroo, Masahiro; Tsukimi, Yasuhiro; Yura, Takeshi; Urbahns, Klaus; Yamamoto, Noriyuki; Mogi, Muneto; Fujishima, Hiroshi; Masuda, Tsutomu; Yoshida, Nagahiro; Moriwaki, Toshiya
PA Bayer Healthcare Ag, Germany
SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004052846	A1	20040624	WO 2003-EP13453	20031128
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2508618	A1	20040624	CA 2003-2508618	20031128
	AU 2003294748	A1	20040630	AU 2003-294748	20031128
	EP 1569896	A1	20050907	EP 2003-785688	20031128
	EP 1569896	B1	20070815		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006509018	T	20060316	JP 2004-557951	20031128
	AT 370118	T	20070915	AT 2003-785688	20031128
	US 2006128704	A1	20060615	US 2005-537482	20051118
PRAI	EP 2002-27523	A	20021206		
	WO 2003-EP13453	W	20031128		
OS	MARPAT 141:71359				
GI					




AB The title compds. I [R1 = H, alkyl; X = biphenyl, etc.] are prepared The tetrahydronaphthalene derivs. of the present invention have excellent activity as VR1 antagonists and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, etc. The bioactivity of I was demonstrated.

IT 711016-15-8P 711016-16-9P 711016-18-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrahydronaphthalene derivs. as vaniloid receptor antagonists)


RN 711016-15-8 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 3',4'-difluoro-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711016-16-9 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 4'-(dimethylamino)-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711016-18-1 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxamide, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

5.74	178.05
------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

-0.78	-0.78
-------	-------

STN INTERNATIONAL LOGOFF AT 09:19:40 ON 07 DEC 2007

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 18:00:44 ON 06 DEC 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 18:00:54 ON 06 DEC 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 DEC 2007 HIGHEST RN 956828-07-2
DICTIONARY FILE UPDATES: 5 DEC 2007 HIGHEST RN 956828-07-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:



<http://www.cas.org/support/stngen/stndoc/properties.html>

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>

Uploading C:\Program Files\Stnexp\Queries\10537482 nsp.str



chain nodes :

11 12 13 14 15 16 17

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :
 3-11 7-13 11-12 13-14 13-17 14-15 14-16
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
 exact/norm bonds :
 1-2 1-6 2-3 3-4 3-11 4-5 7-13 13-14 14-16
 exact bonds :
 11-12 13-17 14-15
 normalized bonds :
 5-6 5-7 6-10 7-8 8-9 9-10

Match level :
 1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
 10:CLASS 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom

L1 STRUCTURE UPLOADED


=> que L1

L2 QUE L1

=> d L1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s L1 full

FULL SEARCH INITIATED 18:01:17 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 112090 TO ITERATE

100.0% PROCESSED 112090 ITERATIONS

72 ANSWERS

SEARCH TIME: 00.00.01

L3 72 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 18:01:23 ON 06 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Dec 2007 VOL 147 ISS 24
FILE LAST UPDATED: 5 Dec 2007 (20071205/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s L3

L4 6 L3

=> d L4 1-6 bib abs hitstr

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:798284 CAPLUS
DN 147:269568
TI Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors
AU Steiner, Alexandre A.; Turek, Victoria F.; Almeida, Maria C.; Burmeister, Jeffrey J.; Oliveira, Daniela L.; Roberts, Jennifer L.; Bannon, Anthony W.; Norman, Mark H.; Louis, Jean-Claude; Treanor, James J. S.; Gavva, Narendra R.; Romanovsky, Andrej A.
CS Systemic Inflammation Laboratory, Trauma Research, St. Joseph's Hospital, Phoenix, AZ, 85013, USA
SO Journal of Neuroscience (2007), 27(28), 7459-7468
CODEN: JNRSDS; ISSN: 0270-6474
PB Society for Neuroscience
DT Journal
LA English
AB An involvement of the transient receptor potential vanilloid (TRPV) 1 channel in the regulation of body temperature (Tb) has not been established decisively. To provide decisive evidence for such an involvement and determine its mechanisms were the aims of the present study. We synthesized a new TRPV1 antagonist, AMG0347 [(E)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-3-(2-(piperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl)acrylamide], and characterized it in vitro. We then found that this drug is the most potent TRPV1 antagonist known to increase Tb of rats and mice and showed (by using knock-out mice) that the entire hyperthermic effect of AMG0347 is TRPV1 dependent. AMG0347-induced hyperthermia was brought about by one or both of the two major autonomic cold-defense effector mechanisms (tail-skin vasoconstriction and/or thermogenesis), but it did not involve warmth-seeking behavior. The magnitude of the hyperthermic response depended on neither Tb nor tail-skin temperature at the time of AMG0347 administration, thus indicating that AMG0347-induced hyperthermia results from blockade of tonic TRPV1 activation by nonthermal factors. AMG0347 was no more effective in causing hyperthermia when administered into the brain (intracerebroventricularly) or spinal cord (intrathecally) than when given systemically (i.v.), which indicates a peripheral site of action. We then established that localized intra-abdominal desensitization of

TRPV1 channels with i.p. resiniferatoxin blocks the Tb response to systemic AMG0347; the extent of desensitization was determined by using a comprehensive battery of functional tests. We conclude that tonic activation of TRPV1 channels in the abdominal viscera by yet unidentified nonthermal factors inhibits skin vasoconstriction and thermogenesis, thus having a suppressive effect on Tb.


IT 946615-43-6, AMG 0347

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TRPV1 antagonist; nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors)

RN 946615-43-6 CAPLUS

CN 2-Propenamide, 3-[2-(1-piperidinyl)-6-(trifluoromethyl)-3-pyridinyl]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2007:88232 CAPLUS

DN 146:163039

TI Preparation of novel 2-(bicyclic heterocyclidene)acetamide derivatives as antagonists of transient receptor potential type 1 (TRPV1)

IN Uchida, Hideharu; Kosuga, Naoto; Satoh, Tsutomu; Hotta, Daido; Kamino, Tomoyuki; Maeda, Yoshitaka; Amano, Ken-Ichi; Akada, Yasushige

PA Mochida Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 237pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007010383	A1	20070125	WO 2006-IB2016	20060724
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI JP 2005-213534	A	20050722		

JP 2005-330890 A 20051115

JP 2006-45985 A 20060222

OS MARPAT 146:163039

GI




AB The title compds. (I) or salts thereof, and solvates of any of them [m, n, p = an integer of 0-2; q = 0, 1; R1 = halo, each (un)substituted hydrocarbyl, heterocyclyl, C1-6 alkoxy, C1-6 alkoxy carbonyl, NH2, HO, CO2H, CONH2, or SO2NH2, C1-6 alkanoyl, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, cyano, NO2; R2 = halo, (un)substituted NH2, hydrocarbyl, or aromatic heterocyclyl, oxo; or two geminal or vicinal R2s together form C2-6 alkylene; R2 and the carbon atom attached to R2 together form a cyclic ring; X1 = O, (un)substituted NH, S, SO, SO2; X2 = CH2, O, (un)substituted NH, S, SO, SO2; Q1 = each (un)substituted heteroaryl, heteroarylalkyl, aryl, or aralkyl; the Cy ring = 5- or 6-membered aryl or heteroaryl; a dotted line represents the condensation of two rings; a wavy line represent E or Z configuration; some exceptions are defined] are prepared These compds. are useful for the treatment or prevention of pains. Thus, tri-Et phosphonoacetate was treated with NaH in THF at $\leq 20^\circ$ for 1 h and condensed with 4-chromanone at room temperature overnight to give (E)-(chroman-4-ylidene)acetic acid Et ester which was refluxed in aqueous THF solution containing LiOH and neutralized with 1 N


aqueous HCl solution to give (E)-(chroman-4-ylidene)acetic acid (II). II was condensed with 1,4-benzodioxan-6-amine using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in CH2Cl2 at room temperature overnight to give (E)-2-(chroman-4-ylidene)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acetamide (III). III and (E)-2-(8-trifluoromethyl-3,4-dihydrobenzo[b]oxepin-5(2H)-ylidene)-N-(quinoxalin-6-yl)acetamide in vitro showed A2 of ≥ 100 nM and < 100 nM, resp., for antagonizing the capsaicin-induced cellular influx of Ca in CHO cell expressing human TRPV1. Pharmaceutical formulations, e.g. a tablet containing (E)-2-(7-tert-Butylchroman-4-ylidene)-N-(5,6,7,8-tetrahydroquinolin-7-yl)acetamide, were prepared

IT 851266-66-5P, 2-Bromo-N-(7-hydroxy-5,6,7,8-tetrahydro-1-naphthyl)acetamide 920334-71-0P, 2-[(2,2-Dimethyl-7-trifluoromethyl-2H-1,3-benzoxazin-4-yl)thio]-N-(7-hydroxy-5,6,7,8-tetrahydro-1-naphthyl)acetamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of novel 2-(bicyclic heterocyclidene)acetamide derivs. as antagonists of transient receptor potential type 1 (TRPV1) for treatment or prevention of pains)

RN 851266-66-5 CAPLUS
CN Acetamide, 2-bromo-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 920334-71-0 CAPLUS
 CN Acetamide, 2-[[2,2-dimethyl-7-(trifluoromethyl)-2H-1,3-benzoxazin-4-yl]thio]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




IT 920332-20-3P, 2-[(E)-8-Trifluoromethyl-3,4-dihydrobenzo[b]oxepin-5(2H)-ylidene]-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-21-4P, 2-[(E)-8-Trifluoromethyl-3,4-dihydrobenzo[b]oxepin-5(2H)-ylidene]-N-((7S)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920333-97-7P,
 (E)-2-(7-Trifluoromethyl-2,2-dimethylchroman-4-ylidene)-N-((7S)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel 2-(bicyclic heterocyclidene)acetamide derivs. as antagonists of transient receptor potential type 1 (TRPV1) for treatment or prevention of pains)

RN 920332-20-3 CAPLUS
 CN Acetamide, 2-[3,4-dihydro-8-(trifluoromethyl)-1-benzoxepin-5(2H)-ylidene]-N-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-, (2E)- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 920332-21-4 CAPLUS

CN Acetamide, 2-[3,4-dihydro-8-(trifluoromethyl)-1-benzoxepin-5(2H)-ylidene]-N-[(7S)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-, (2E)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 920333-97-7 CAPLUS


CN Acetamide, 2-[2,3-dihydro-2,2-dimethyl-7-(trifluoromethyl)-4H-1-benzopyran-4-ylidene]-N-[(7S)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



IT 920333-95-5P, (Z)-2-(6-Trifluoromethyl-3,3-dimethyl-4-oxa-3,4-dihydro-2H-isoquinolin-1-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of novel 2-(bicyclic heterocyclidene)acetamide derivs. as antagonists of transient receptor potential type 1 (TRPV1) for treatment or prevention of pains)
 RN 920333-95-5 CAPLUS
 CN Acetamide, 2-[2,3-dihydro-2,2-dimethyl-7-(trifluoromethyl)-4H-1,3-benzoxazin-4-ylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2Z)- (CA INDEX NAME)

Double bond geometry as described by E or Z.



IT 920332-19-0P, (E)-2-[8-Trifluoromethyl-3,4-dihydrobenzo[b]oxepin-5(2H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide
 920332-27-0P, (E)-2-(7-Trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-28-1P
 , (E)-2-(7-Trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-29-2P,
 (E)-2-(7-Trifluoromethylchroman-4-ylidene)-N-((7S)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-39-4P,
 (E)-2-[1-(Cyclopentylcarbonyl)-7-trifluoromethyl-2,3-dihydroquinolin-4(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide
 920332-40-7P, (E)-2-(1-Pentanoyl-7-trifluoromethyl-2,3-dihydroquinolin-4(1H)-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-41-8P, (E)-2-[1-(Cyclobutylcarbonyl)-7-trifluoromethyl-2,3-dihydroquinolin-4(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-42-9P,
 (E)-2-[1-[(4,4-Difluorocyclohexyl)carbonyl]-7-trifluoromethyl-2,3-dihydroquinolin-4(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-43-0P, (E)-2-[1-(4-Methylpentanoyl)-7-trifluoromethyl-2,3-dihydroquinolin-4(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-44-1P,

(E)-2-[1-(3-Methylbutanoyl)-7-trifluoromethyl-2,3-dihydroquinolin-4(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-45-2P, (E)-2-[1-[(1-Methylcyclopropyl)carbonyl]-7-trifluoromethyl-2,3-dihydroquinolin-4(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-46-3P, (E)-2-[1-[(1-Methylcyclobutyl)carbonyl]-7-trifluoromethyl-2,3-dihydroquinolin-4(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-47-4P, (E)-2-[1-(4,4,4-Trifluorobutanoyl)-7-trifluoromethyl-2,3-dihydroquinolin-4(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-48-5P, (E)-2-[1-(3,3,3-Trifluoropropanoyl)-7-trifluoromethyl-2,3-dihydroquinolin-4(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-49-6P, (E)-2-[1-(5,5,5-Trifluoropentanoyl)-7-trifluoromethyl-2,3-dihydroquinolin-4(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-50-9P, (E)-2-[1-(Phenylacetyl)-7-trifluoromethyl-2,3-dihydroquinolin-4(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-51-0P, (E)-2-[1-(2,2-Difluorobutanoyl)-7-trifluoromethyl-2,3-dihydroquinolin-4(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-52-1P, (E)-2-[1-(2-Fluoro-2-methylpropanoyl)-7-trifluoromethyl-2,3-dihydroquinolin-4(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-61-2P, (E)-2-[7-Trifluoromethyl-2,3-dihydro-1-(cyclopropylcarbonyl)quinolin-4(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-62-3P, (E)-2-(7-Trifluoromethyl-2,3-dihydroquinolin-4(1H)-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-65-6P, (E)-2-[7-Trifluoromethyl-2,3-dihydro-1-[(2,2-dimethylcyclopropyl)carbonyl]quinolin-4(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-66-7P, (E)-2-[7-Trifluoromethyl-2,3-dihydro-1-(2-furancarboxyl)quinolin-4(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-67-8P, (E)-2-[1-[(1-Hydroxycyclopropyl)carbonyl]-7-trifluoromethyl-2,3-dihydroquinolin-4(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-68-9P, (E)-2-[1-[(3,3-Difluoroazetidin-1-yl)carbonyl]-7-trifluoromethyl-2,3-dihydroquinolin-4(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-69-0P, (E)-2-(1-Formyl-7-trifluoromethyl-2,3-dihydroquinolin-4(1H)-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-70-3P, (E)-2-[1-[(1-Fluorocyclopentyl)carbonyl]-7-trifluoromethyl-2,3-dihydroquinolin-4(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-71-4P, (E)-2-[1-(3,3-Difluorobutanoyl)-7-trifluoromethyl-2,3-dihydroquinolin-4(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-72-5P, (E)-2-[1-(3,3-Difluoropentanoyl)-7-trifluoromethyl-2,3-dihydroquinolin-4(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920332-73-6P, (E)-2-[1-[(3,3-Difluorocyclobutyl)carbonyl]-7-trifluoromethyl-2,3-dihydroquinolin-4(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920333-45-5P, (E)-2-(8-Trifluoromethyl-1-pentanoyl-1,2,3,4-tetrahydro-5H-benz[b]azepin-5-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920333-54-6P, (E)-2-(1-Methyl-8-trifluoromethyl-1,2,3,4-tetrahydro-5H-benz[b]azepin-5-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920333-55-7P, (E)-2-(1-(3-Chloro-5-hydroxymethyl-pyridin-2-yl)-7-trifluoromethyl-2,3-dihydroquinolin-4(1H)-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920333-61-5P, (E)-2-(7-Isopropylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920333-63-7P, (E)-2-(7-Chlorochroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920333-65-9P, (E)-2-(7-Trifluoromethoxychroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920333-67-1P, (E)-2-[7-(1,1,2,2-Tetrafluoroethoxy)chroman-4-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920333-69-3P,


(E)-2-(6-Fluoro-7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920333-72-8P,
 (E)-2-(7-Trifluoromethyl-3,3-difluorochroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920333-90-0P,
 (E)-2-[8-Trifluoromethyl-3,4-dihydrobenzo[c]isooxepin-5(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920333-92-2P
 , (E)-2-(7-Trifluoromethylisochroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920333-93-3P,
 (E)-2-(7-Trifluoromethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide
 920333-94-4P, (E)-2-(8-Trifluoromethyl-2,3,4,5-tetrahydrooxepino[2,3-b]pyridin-5-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920333-96-6P,
 (E)-2-(7-Trifluoromethyl-2,2-dimethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920333-98-8P,
 (E)-2-(7-Trifluoromethyl-2,2-dimethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920334-03-8P,
 (E)-2-[7-Fluoro-8-trifluoromethyl-3,4-dihydrobenzo[b]oxepin-5(2H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide
 920334-04-9P, (E)-2-(6-Trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920334-06-1P
 , (E)-2-(7-Trifluoromethyl-2,2-dicyclobutylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920513-93-5P,
 (E)-2-[1-[(3-Fluorocyclopentyl)carbonyl]-7-trifluoromethyl-2,3-dihydroquinolin-4(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 920513-94-6P, (E)-2-[7-Trifluoromethyl-2,3-dihydro-1-[[4-(trifluoromethyl)cyclohexyl]carbonyl]quinolin-4(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel 2-(bicyclic heterocyclidene)acetamide derivs. as antagonists of transient receptor potential type 1 (TRPV1) for treatment or prevention of pains)

RN 920332-19-0 CAPLUS

CN Acetamide, 2-[3,4-dihydro-8-(trifluoromethyl)-1-benzoxepin-5(2H)-ylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 920332-27-0 CAPLUS

CN Acetamide, 2-[2,3-dihydro-7-(trifluoromethyl)-4H-1-benzopyran-4-ylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 920332-28-1 CAPLUS

CN Acetamide, 2-[2,3-dihydro-7-(trifluoromethyl)-4H-1-benzopyran-4-ylidene]-N-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.




RN 920332-29-2 CAPLUS

CN Acetamide, 2-[2,3-dihydro-7-(trifluoromethyl)-4H-1-benzopyran-4-ylidene]-N-[(7S)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as described by E or Z.



RN 920332-39-4 CAPLUS

CN Acetamide, 2-[1-(cyclopentylcarbonyl)-2,3-dihydro-7-(trifluoromethyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920332-40-7 CAPLUS

CN Acetamide, 2-[2,3-dihydro-1-(1-oxopentyl)-7-(trifluoromethyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)-(CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920332-41-8 CAPLUS

CN Acetamide, 2-[1-(cyclobutylcarbonyl)-2,3-dihydro-7-(trifluoromethyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)-(CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920332-42-9 CAPLUS

CN Acetamide, 2-[1-[(4,4-difluorocyclohexyl)carbonyl]-2,3-dihydro-7-(trifluoromethyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920332-43-0 CAPLUS

CN Acetamide, 2-[2,3-dihydro-1-(4-methyl-1-oxopentyl)-7-(trifluoromethyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920332-44-1 CAPLUS

CN Acetamide, 2-[2,3-dihydro-1-(3-methyl-1-oxobutyl)-7-(trifluoromethyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920332-45-2 CAPLUS

CN Acetamide, 2-[2,3-dihydro-1-[(1-methylcyclopropyl)carbonyl]-7-(trifluoromethyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920332-46-3 CAPLUS

CN Acetamide, 2-[2,3-dihydro-1-[(1-methylcyclobutyl)carbonyl]-7-(trifluoromethyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920332-47-4 CAPLUS

CN Acetamide, 2-[2,3-dihydro-7-(trifluoromethyl)-1-(4,4,4-trifluoro-1-oxobutyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920332-48-5 CAPLUS

CN Acetamide, 2-[2,3-dihydro-7-(trifluoromethyl)-1-(3,3,3-trifluoro-1-oxopropyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920332-49-6 CAPLUS

CN Acetamide, 2-[2,3-dihydro-7-(trifluoromethyl)-1-(5,5,5-trifluoro-1-oxopentyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920332-50-9 CAPLUS

CN Acetamide, 2-[2,3-dihydro-1-(2-phenylacetyl)-7-(trifluoromethyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 920332-51-0 CAPLUS

CN Acetamide, 2-[1-(2,2-difluoro-1-oxobutyl)-2,3-dihydro-7-(trifluoromethyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)

4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-,
(2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920332-52-1 CAPLUS

CN Acetamide, 2-[1-(2-fluoro-2-methyl-1-oxopropyl)-2,3-dihydro-7-(trifluoromethyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920332-61-2 CAPLUS

CN Acetamide, 2-[1-(cyclopropylcarbonyl)-2,3-dihydro-7-(trifluoromethyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920332-62-3 CAPLUS

CN Acetamide, 2-[2,3-dihydro-7-(trifluoromethyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920332-65-6 CAPLUS

CN Acetamide, 2-[1-[(2,2-dimethylcyclopropyl)carbonyl]-2,3-dihydro-7-(trifluoromethyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 920332-66-7 CAPLUS

CN Acetamide, 2-[1-(2-furanylcarbonyl)-2,3-dihydro-7-(trifluoromethyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)-

(CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920332-67-8 CAPLUS

CN Acetamide, 2-[2,3-dihydro-1-[(1-hydroxycyclopropyl)carbonyl]-7-(trifluoromethyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920332-68-9 CAPLUS

CN Acetamide, 2-[1-[(3,3-difluoro-1-azetidiny)carbonyl]-2,3-dihydro-7-(trifluoromethyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920332-69-0 CAPLUS

CN Acetamide, 2-[1-formyl-2,3-dihydro-7-(trifluoromethyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)-(CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920332-70-3 CAPLUS

CN Acetamide, 2-[1-[(1-fluorocyclopentyl)carbonyl]-2,3-dihydro-7-(trifluoromethyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)-(CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920332-71-4 CAPLUS

CN Acetamide, 2-[1-(3,3-difluoro-1-oxobutyl)-2,3-dihydro-7-(trifluoromethyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920332-72-5 CAPLUS


CN Acetamide, 2-[1-(3,3-difluoro-1-oxopentyl)-2,3-dihydro-7-(trifluoromethyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 920332-73-6 CAPLUS
 CN Acetamide, 2-[1-[(3,3-difluorocyclobutyl)carbonyl]-2,3-dihydro-7-(trifluoromethyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 920333-45-5 CAPLUS
 CN Acetamide, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-2-[1,2,3,4-tetrahydro-1-(1-oxopentyl)-8-(trifluoromethyl)-5H-1-benzazepin-5-ylidene]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 920333-54-6 CAPLUS
 CN Acetamide, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-2-[1,2,3,4-tetrahydro-1-methyl-8-(trifluoromethyl)-5H-1-benzazepin-5-ylidene]-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 920333-55-7 CAPLUS

CN Acetamide, 2-[1-[3-chloro-5-(hydroxymethyl)-2-pyridinyl]-2,3-dihydro-7-(trifluoromethyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920333-61-5 CAPLUS

CN Acetamide, 2-[2,3-dihydro-7-(1-methylethyl)-4H-1-benzopyran-4-ylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920333-63-7 CAPLUS

CN Acetamide, 2-(7-chloro-2,3-dihydro-4H-1-benzopyran-4-ylidene)-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920333-65-9 CAPLUS

CN Acetamide, 2-[2,3-dihydro-7-(trifluoromethoxy)-4H-1-benzopyran-4-ylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920333-67-1 CAPLUS

CN Acetamide, 2-[2,3-dihydro-7-(1,1,2,2-tetrafluoroethoxy)-4H-1-benzopyran-4-ylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920333-69-3 CAPLUS

CN Acetamide, 2-[6-fluoro-2,3-dihydro-7-(trifluoromethyl)-4H-1-benzopyran-4-ylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920333-72-8 CAPLUS

CN Acetamide, 2-[3,3-difluoro-2,3-dihydro-7-(trifluoromethyl)-4H-1-benzopyran-4-ylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 920333-90-0 CAPLUS

CN Acetamide, 2-[3,4-dihydro-8-(trifluoromethyl)-2-benzoxepin-5(1H)-ylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 920333-92-2 CAPLUS

CN Acetamide, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-2-[7-(trifluoromethyl)-1H-2-benzopyran-4(3H)-ylidene]-, (2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920333-93-3 CAPLUS

CN Acetamide, 2-[2,3-dihydro-7-(trifluoromethyl)-4H-pyrano[2,3-b]pyridin-4-ylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920333-94-4 CAPLUS

CN Acetamide, 2-[3,4-dihydro-8-(trifluoromethyl)oxepino[2,3-b]pyridin-5(2H)-ylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 920333-96-6 CAPLUS

CN Acetamide, 2-[2,3-dihydro-2,2-dimethyl-7-(trifluoromethyl)-4H-1-benzopyran-4-ylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 920333-98-8 CAPLUS

CN Acetamide, 2-[2,3-dihydro-2,2-dimethyl-7-(trifluoromethyl)-4H-1-benzopyran-4-ylidene]-N-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as described by E or Z.



RN 920334-03-8 CAPLUS

CN Acetamide, 2-[7-fluoro-3,4-dihydro-8-(trifluoromethyl)-1-benzoxepin-5(2H)-ylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 920334-04-9 CAPLUS

CN Acetamide, 2-[2,3-dihydro-6-(trifluoromethyl)-4H-1-benzopyran-4-ylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920334-06-1 CAPLUS

CN Acetamide, 2-[2,2-dicyclobutyl-2,3-dihydro-7-(trifluoromethyl)-4H-1-benzopyran-4-ylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920513-93-5 CAPLUS

CN Acetamide, 2-[1-[(3-fluorocyclopentyl)carbonyl]-2,3-dihydro-7-(trifluoromethyl)-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 920513-94-6 CAPLUS

CN Acetamide, 2-[2,3-dihydro-7-(trifluoromethyl)-1-[[4-(trifluoromethyl)cyclohexyl]carbonyl]-4(1H)-quinolinylidene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as described by E or Z.



RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:395257 CAPLUS

DN 142:447018

TI Preparation of tetrahydronaphthalene and urea derivatives as VR1 antagonists for the prophylaxis and treatment of diseases associated with VR1 activity, such as urological diseases, pain and inflammatory diseases

IN Bouchon, Axel; Diedrichs, Nicole; Hermann, Achim; Lustig, Klemens; Meier, Heinrich; Pernerstorfer, Josef; Reissmueller, Elke; Mogi, Muneto; Yura, Takeshi; Fujishima, Hiroshi; Seki, Masaomi; Koriyama, Yuji; Yasoshima, Kayo; Misawa, Keiko; Tajimi, Masaomi; Yamamoto, Noriyuki; Urbahns, Klaus; Hayashi, Fumihiko; Tsukimi, Yasuhiro; Gupta, Jang

PA Bayer Healthcare Ag, Germany

SO PCT Int. Appl., 149 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005040100	A1	20050506	WO 2004-EP11008	20041002
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2542494	A1	20050506	CA 2004-2542494	20041002
	EP 1678123	A1	20060712	EP 2004-765763	20041002
	R: DE, ES, FR, GB, IT				
	JP 2007509846	T	20070419	JP 2006-534634	20041002
PRAI	EP 2003-23287	A	20031015		
	EP 2003-23288	A	20031015		
	EP 2003-25572	A	20031108		
	EP 2003-25573	A	20031108		
	WO 2004-EP11008	W	20041002		
OS	CASREACT 142:447018; MARPAT 142:447018				
GI					




II

AB This invention relates to title compds. of formula A-NH-CO-E (I) [wherein A = 7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl, 5,8-dihydrotetranaphthalen-1-yl; indan-4-yl, inden-4-yl, etc.; E = cycloalkyl optionally fused by aryl, (un)substituted Ph, hetero/aryl, NH-(CH₂)_n-R₄, etc.; n = 0-6; R₄ = (un)substituted aryl] and tautomeric or stereoisomers and salts thereof, which are useful as active ingredients of pharmaceutical preps. I have been synthesized as VR1 antagonists, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urol. disorders or diseases, pain and inflammatory disorders or diseases. Thus, reacting (6-Ethoxy-5,8-dihydronaphthalen-1-yl)amine (preparation given) with 4-Chloro-3-trifluoromethylbenzene isocyanate gave II. The effects of the compds. were examined in the following several assays and pharmacol. tests: measurement of capsaicin-induced Ca²⁺ influx in a human VR1-transfected CHO cell line and in primary cultured rat dorsal root ganglia neurons, resp., measurement of capsaicin-induced bladder contraction, measurement of overactive bladder in anesthetized cystitis rats, measurement of acute pain, persistent pain, neuropathic pain, inflammatory pain and diabetic neuropathic pain (only the 1st assay had data). II showed an IC₅₀ in the range of 0.1 to 0.6 μM in the 1st assay. Specifically disclosed applications of I include the treatment of detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor overactivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary


tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD).

IT 711016-23-8P 851266-68-7P, N'-[4-Chloro-3-(trifluoromethyl)phenyl]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)glycinamide 851266-75-6P, N-((7R)-7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-methyl-N'-[4-(trifluoromethoxy)phenyl]glycinamide 851266-76-7P, N-((7R)-7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[4-(trifluoromethoxy)phenyl]glycinamide 851266-79-0P, N-((7R)-7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-2-[4-(trifluoromethyl)phenyl]acetamide 851266-80-3P, N-((7R)-7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-3-[4-(trifluoromethyl)phenyl]propanamide 851266-81-4P, N-((7R)-7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-2-[4-(trifluoromethoxy)phenyl]acetamide 851266-82-5P, 2-(4-Chlorophenoxy)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 851266-83-6P, 2-(2,4-Difluorophenoxy)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 851266-84-7P, 2-[2-Chloro-4-(trifluoromethyl)phenoxy]-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 851266-85-8P, N-((7R)-7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-2-[4-(trifluoromethyl)phenoxy]acetamide 851266-86-9P, N-((7R)-7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-2-[4-(trifluoromethoxy)phenoxy]acetamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of tetrahydronaphthalene and urea derivs. as VR1 antagonists)

RN 711016-23-8 CAPLUS
 CN Benzeneacetamide, 3-bromo-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-(CA INDEX NAME)




RN 851266-68-7 CAPLUS
 CN Acetamide, 2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-(CA INDEX NAME)



RN 851266-75-6 CAPLUS

CN Acetamide, 2-[methyl[4-(trifluoromethoxy)phenyl]amino]-N-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 851266-76-7 CAPLUS

CN Acetamide, N-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-2-[[4-(trifluoromethoxy)phenyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 851266-79-0 CAPLUS

CN Benzeneacetamide, N-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-4-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851266-80-3 CAPLUS

CN Benzenepropanamide, N-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-4-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851266-81-4 CAPLUS

CN Benzeneacetamide, N-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-4-(trifluoromethoxy)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851266-82-5 CAPLUS

CN Acetamide, 2-(4-chlorophenoxy)-N-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 851266-83-6 CAPLUS

CN Acetamide, 2-(2,4-difluorophenoxy)-N-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 851266-84-7 CAPLUS

CN Acetamide, 2-[2-chloro-4-(trifluoromethyl)phenoxy]-N-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 851266-85-8 CAPLUS

CN Acetamide, N-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-2-[4-(trifluoromethyl)phenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 851266-86-9 CAPLUS

CN Acetamide, N-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-2-[4-(trifluoromethoxy)phenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



IT 851266-66-5P, 2-Bromo-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 851266-71-2P, 2-Bromo-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of tetrahydronaphthalene and urea derivs. as VR1 antagonists)

RN 851266-66-5 CAPLUS


CN Acetamide, 2-bromo-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 851266-71-2 CAPLUS

CN Acetamide, 2-bromo-N-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:515474 CAPLUS
DN 141:71359
TI Preparation of tetrahydronaphthalene derivatives as vaniloid receptor antagonists
IN Tajimi, Masaomi; Kokubo, Toshio; Shiroo, Masahiro; Tsukimi, Yasuhiro; Yura, Takeshi; Urbahns, Klaus; Yamamoto, Noriyuki; Mogi, Muneto; Fujishima, Hiroshi; Masuda, Tsutomu; Yoshida, Nagahiro; Moriwaki, Toshiya
PA Bayer Healthcare Ag, Germany
SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2004052846	A1	20040624	WO 2003-EP13453	20031128	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:			BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	CA 2508618	A1	20040624	CA 2003-2508618	20031128	
	AU 2003294748	A1	20040630	AU 2003-294748	20031128	
	EP 1569896	A1	20050907	EP 2003-785688	20031128	
	EP 1569896	B1	20070815			
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK		
	JP 2006509018	T	20060316	JP 2004-557951	20031128	
	AT 370118	T	20070915	AT 2003-785688	20031128	
	US 2006128704	A1	20060615	US 2005-537482	20051118	
PRAI	EP 2002-27523	A	20021206			
	WO 2003-EP13453	W	20031128			
OS	MARPAT 141:71359					
GI						



AB The title compds. I [R1 = H, alkyl; X = biphenyl, etc.] are prepared The tetrahydronaphthalene derivs. of the present invention have excellent activity as VR1 antagonists and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, etc. The bioactivity of I was demonstrated.


IT 711016-20-5P 711016-21-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tetrahydronaphthalene derivs. as vaniloid receptor antagonists)


RN 711016-20-5 CAPLUS

CN [1,1'-Biphenyl]-3-acetamide, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711016-21-6 CAPLUS

CN [1,1'-Biphenyl]-3-acetamide, 4'-fluoro-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)





IT 711016-23-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of tetrahydronaphthalene derivs. as vaniloid receptor
 antagonists)
 RN 711016-23-8 CAPLUS
 CN Benzeneacetamide, 3-bromo-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-
 (CA INDEX NAME)



L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1998:146695 CAPLUS
 DN 128:192670
 TI Preparation of fused cycloalkylquinoxalinediones as glutamate receptor
 antagonists
 IN Bigge, Christopher Franklin; Retz, Daniel Martin
 PA Warner-Lambert Co., USA
 SO U.S., 40 pp., Cont.-in-part of U.S. Ser. No. 350,765, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5721234	A	19980224	US 1995-534526	19951023
	WO 9617832	A1	19960613	WO 1995-US14571	19951107
	W: AU, CA, CZ, EE, HU, JP, LT, LV, MX, NZ, PL, RO, RU, SI, SK				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9641522	A	19960626	AU 1996-41522	19951107
	ZA 9510375	A	19960613	ZA 1995-10375	19951206

PRAI US 1994-350765 B2 19941207
 US 1995-534526 A 19951023
 WO 1995-US14571 W 19951107
 OS MARPAT 128:192670
 GI




AB Title compds. [I; R = Z1R2; R1 = H, alkyl, aralkyl; X, Y = H, halo, NO2, etc.; R2 = H, alkyl, alkoxy, aryl, etc.; Z = (CH2)1-3; Z1 = O, CO, CH2, (alkyl)imino, etc.], useful in treatment of anxiety, cerebral ischemia, Parkinsonism and epilepsy, were prepared Cyclization of naphthalenol II with (CO2H)2 gave I [R = 9-OH; R1 = Y = H; X = Br; Z = CH2CH2] which showed IC50 of 17 μ M against AMPA.

IT 179266-27-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of fused cycloalkylquinoxalinediones as glutamate receptor antagonists)

RN 179266-27-4 CAPLUS

CN Acetamide, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1996:464552 CAPLUS
 DN 125:114711
 TI Preparation of fused cycloalkylquinoxalinediones as glutamate receptor antagonists
 IN Bigge, Christopher Franklin; Retz, Daniel Martin
 PA Warner-Lambert Company, USA
 SO PCT Int. Appl., 139 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9617832	A1	19960613	WO 1995-US14571	19951107
	W: AU, CA, CZ, EE, HU, JP, LT, LV, MX, NZ, PL, RO, RU, SI, SK				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5721234	A	19980224	US 1995-534526	19951023
	AU 9641522	A	19960626	AU 1996-41522	19951107
PRAI	US 1994-350765	A	19941207		

US 1995-534526 A 19951023
 WO 1995-US14571 W 19951107
 OS CASREACT 125:114711; MARPAT 125:114711
 GI




AB The title compds. [I; R1 = H, alkyl, arylalkyl; X, Y = H, halo, NO2, etc.; A = O, (substituted) NH, CN, etc.; when A = CO then B = OH, alkoxy, araloxy, etc.; n = 1-3], useful in treatment of anxiety, cerebral ischemia, Parkinsonism and epilepsy, were prepared Cyclization of naphthalenol II with oxalic acid in 2N HCl at 90° afforded I [R1 = H; X = Br; Y = H; A = 9-OH; n = 2] which showed IC50 of 17 μM against AMPA.

IT 179266-27-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of fused cycloalkylquinoxalinediones as glutamate receptor antagonists)

RN 179266-27-4 CAPLUS

CN Acetamide, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

32.09

204.40

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-4.68

-4.68

STN INTERNATIONAL LOGOFF AT 18:02:03 ON 06 DEC 2007

***** QUERY RESULTS *****

=> d his 19

(FILE 'HCAPLUS' ENTERED AT 16:21:29 ON 26 NOV 2007)

L9 6 S L6








=> d que 19

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation:

Uploading L8.str



chain nodes :

11 12 13 14 15 16 17 22 24 26 27 28 29 30

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

3-11 7-12 12-13 13-14 13-22 15-29 16-17 17-24 24-28 26-27 29-30

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

exact/norm bonds :

1-2 1-6 2-3 3-4 3-11 4-5 5-6 5-7 6-10 7-8 7-12 8-9 9-10 12-13 13-14

13-22 15-29 16-17 17-24 24-28 26-27 29-30

isolated ring systems :

containing 1 :

G1: [*1], [*2], [*3]

G2

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 22:CLASS

24:CLASS 26:Atom

27:Atom 28:Atom 29:Atom 30:Atom

Generic attributes :

24:

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

26:

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

27:

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

28:

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

29:

Number of Carbon Atoms : less than 7


Type of Ring System : Monocyclic

30:

Number of Carbon Atoms : less than 7


Type of Ring System : Monocyclic

L3 106 SEA FILE=REGISTRY SSS FUL L1
L4 STR



Structure attributes must be viewed using STN Express query preparation

Uploading L4.str



ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12

chain bonds :

5-9

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

exact bonds :

5-9

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

isolated ring systems :

containing 1 : 7 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom

L6 105 SEA FILE=REGISTRY SUB=L3 SSS FUL L4
 L9 6 SEA FILE=HCAPLUS ABB=ON PLU=ON L6

=> d.19 bib ed abs hitstr hitind 1-6

L9 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:61322 HCAPLUS Full-text

DOCUMENT NUMBER: 146:162916

TITLE: Preparation of biphenyl carboxylic acid derivatives as apoptosis promoters

INVENTOR(S): Wendt, Michael D.; Shen, Wang; Dickman, Daniel A.; Ding, Hong; Thomas, Sheela A.; Augeri, David; Elmore, Steven W.

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: PCT Int. Appl., 69pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007008627	A2	20070118	WO 2006-US26424	20060707
WO 2007008627	A3	20070315		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				


US 2007135392 A1 20070614 US 2006-482458 20060707

PRIORITY APPLN. INFO.: US 2005-697123P P 20050707

OTHER SOURCE(S): MARPAT 146:162916

ED Entered STN: 19 Jan 2007

GI



AB Title compds. represented by the formula 1-A1-3-B1-6-C1-benzene [I: wherein A1 = (un)substituted alkyl, alkoxy, sulfonylamino, etc.; B1 = independently F, Br, Cl or I; C1 = CN, CO₂OH, sulfonylalkyl, etc.; and pharmaceutically

acceptable salts thereof] were prepared as apoptosis promoters. For example, II was provided in a multi-step synthesis starting from the coupling reaction of Me 4-chloro-2-methoxybenzoate with 4-fluorobenzenboronic acid. The invention compds. demonstrated the utility as binders to and inhibitors of anti-apoptotic Mcl-1 protein. Thus, I and their pharmaceutical compns. are useful as apoptosis promoters for the treatment of cancers.


IT 920747-30-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of biphenyl carboxylic acid derivs. as apoptosis promoters)

RN 920747-30-4 HCAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-fluoro-3-[[7-hydroxy-1-naphthalenyl)amino]carbonyl]- (CA INDEX NAME)



CC 25-17 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)

Section cross-reference(s): 1, 63

IT	920746-13-0P	920746-14-1P	920746-15-2P	920746-16-3P	920746-17-4P
	920746-18-5P	920746-19-6P	920746-20-9P	920746-21-0P	920746-22-1P
	920746-23-2P	920746-24-3P	920746-25-4P	920746-26-5P	920746-27-6P
	920746-28-7P	920746-29-8P	920746-30-1P	920746-31-2P	920746-33-4P
	920746-35-6P	920746-37-8P	920746-40-3P	920746-43-6P	920746-45-8P
	920746-47-0P	920746-49-2P	920746-52-7P	920746-54-9P	920746-57-2P
	920746-58-3P	920746-60-7P	920746-61-8P	920746-63-0P	920746-64-1P
	920746-65-2P	920746-66-3P	920746-67-4P	920746-68-5P	920746-69-6P
	920746-72-1P	920746-75-4P	920746-78-7P	920746-81-2P	920746-83-4P
	920746-84-5P	920746-85-6P	920746-86-7P	920746-87-8P	920746-88-9P
	920746-90-3P	920746-91-4P	920746-92-5P	920746-93-6P	920746-94-7P
	920746-95-8P	920746-96-9P	920746-97-0P	920746-98-1P	920746-99-2P
	920747-00-8P	920747-01-9P	920747-02-0P	920747-03-1P	920747-04-2P
	920747-05-3P	920747-06-4P	920747-07-5P	920747-08-6P	920747-09-7P
	920747-10-0P	920747-11-1P	920747-12-2P	920747-13-3P	920747-14-4P
	920747-15-5P	920747-16-6P	920747-17-7P	920747-18-8P	920747-19-9P
	920747-20-2P	920747-21-3P	920747-22-4P	920747-23-5P	920747-24-6P
	920747-25-7P	920747-26-8P	920747-27-9P	920747-28-0P	920747-29-1P
	920747-30-4P	920747-31-5P	920747-32-6P	920747-33-7P	
	920747-34-8P	920747-35-9P	920747-36-0P	920747-37-1P	920747-38-2P
	920747-39-3P	920747-40-6P	920747-41-7P	920747-42-8P	920747-43-9P
	920747-44-0P	920747-45-1P	920747-46-2P	920747-47-3P	920747-48-4P
	920747-49-5P	920747-50-8P	920747-51-9P	920747-52-0P	920747-53-1P
	920747-54-2P	920747-55-3P	920747-56-4P	920747-57-5P	920747-58-6P
	920747-59-7P	920747-60-0P	920747-61-1P	920747-62-2P	920747-63-3P
	920747-64-4P	920747-65-5P	920747-66-6P	920747-67-7P	920747-68-8P
	920747-69-9P	920747-70-2P	920747-71-3P	920747-72-4P	920747-73-5P
	920747-74-6P	920747-75-7P	920747-76-8P	920747-77-9P	920747-78-0P
	920747-79-1P	920747-80-4P	920747-81-5P	920747-82-6P	920747-83-7P

920747-84-8P	920747-85-9P	920747-86-0P	920747-87-1P	920747-88-2P
920747-89-3P	920747-90-6P	920747-91-7P	920747-92-8P	920747-93-9P
920747-94-0P	920747-95-1P	920747-96-2P	920747-97-3P	920747-98-4P
920747-99-5P	920748-00-1P	920748-01-2P	920748-02-3P	920748-03-4P
920748-04-5P	920748-05-6P	920748-06-7P	920748-07-8P	920748-08-9P
920748-09-0P	920748-10-3P	920748-11-4P	920748-12-5P	920748-13-6P
920748-14-7P	920748-15-8P	920748-17-0P	920748-19-2P	920748-21-6P
920748-23-8P	920748-25-0P	920748-27-2P	920748-29-4P	920748-32-9P
920748-34-1P	920748-37-4P	920748-39-6P	920748-41-0P	920748-43-2P
920748-46-5P	920748-48-7P	920748-50-1P	920748-52-3P	920748-53-4P
920748-54-5P	920748-55-6P	920748-56-7P	920748-57-8P	920748-58-9P
920748-59-0P	920748-60-3P	920748-61-4P	920748-62-5P	920748-63-6P
920748-64-7P	920748-65-8P	920748-66-9P	920748-67-0P	920748-68-1P
920748-69-2P	920748-70-5P	920748-71-6P	920748-72-7P	920748-73-8P
920748-74-9P	920748-75-0P	920748-76-1P	920748-77-2P	920748-78-3P
920748-79-4P	920748-80-7P	920748-81-8P	920748-82-9P	920748-83-0P
920748-84-1P	920748-85-2P	920748-87-4P	920748-88-5P	920749-56-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of biphenyl carboxylic acid derivs. as apoptosis promoters)

L9 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1127322 HCAPLUS Full-text

DOCUMENT NUMBER: 142:74358

TITLE: Preparation of benzamide derivatives as capsaicin receptor VR1 activation inhibitors

INVENTOR(S): Kuramochi, Takahiro; Asai, Norio; Ikegai, Kazuhiro; Akamatsu, Seiji; Harada, Hironori; Ishikawa, Noriko; Shirakami, Shohei; Miyamoto, Satoshi; Watanabe, Toshihiro; Kiso, Tetsuo

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 100 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110986	A1	20041223	WO 2004-JP8479	20040610
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004247559	A1	20041223	AU 2004-247559	20040610
CA 2526387	A1	20041223	CA 2004-2526387	20040610
EP 1632477	A1	20060308	EP 2004-736576	20040610
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
CN 1805923	A	20060719	CN 2004-80016215	20040610
BR 2004011083	A	20060725	BR 2004-11083	20040610

10/537482

MX 2005PA13434	A	20060317	MX 2005-PA13434	20051209
US 2007167444	A1	20070719	US 2005-560282	20051212
NO 2006000167	A	20060310	NO 2006-167	20060111
PRIORITY APPLN. INFO.:			JP 2003-167865	A 20030612
			JP 2003-405086	A 20031203
			WO 2004-JP8479	W 20040610


OTHER SOURCE(S): MARPAT 142:74358
 ED Entered STN: 24 Dec 2004
 GI



AB Tittle compds. I [A = NR11R12, etc.; R11, R12 = H, halo, etc.; L = alkylene; ring D, E = mono- or dicyclic hydrocarbon ring, etc.; R1-R9 = H, halo, etc.; R10 = H, alkyl] were prepared For example, HBTU-mediated acylation of 3-methoxyaniline with 2-(piperidin-1-ylmethyl)biphenyl-4- carboxylic acid followed by treatment with HCl afforded compound II. In VR1 receptor binding assays, compound II exhibited the IC50 value of $\leq 1 \mu\text{M}$. Compds. I are claimed useful as VR1 activation inhibitors for the treatment of pains.

IT 813421-19-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzamide derivs. as capsaicin receptor VR1 activation inhibitors for treatment of pains)

RN 813421-19-1 HCAPLUS
 CN [1,1'-Biphenyl]-4-carboxamide, N-(7-hydroxy-1-naphthalenyl)-2-(1-piperidinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IC	ICM	C07C237-40			
	ICS	C07D215-38; C07D217-22; C07D263-58; C07D265-36; C07D277-68; C07D295-14; C07D417-12; A61K031-167; A61K031-428; A61K031-4453; A61K031-454; A61K031-4709; A61K031-4725; A61K031-496; A61K031-5377; A61K031-538; A61K031-55; A61P001-04; A61P011-00			
CC	25-19	(Benzene, Its Derivatives, and Condensed Benzenoid Compounds)			
		Section cross-reference(s): 1			
IT	813420-14-3P	813420-20-1P	813420-24-5P	813420-27-8P	813420-29-0P
	813420-31-4P	813420-35-8P	813420-39-2P	813420-42-7P	813420-45-0P
	813420-48-3P	813420-51-8P	813420-54-1P	813420-56-3P	813420-59-6P
	813420-62-1P	813420-64-3P	813420-66-5P	813420-69-8P	813420-70-1P
	813420-72-3P	813420-73-4P	813420-74-5P	813420-75-6P	813420-76-7P
	813420-77-8P	813420-79-0P	813420-81-4P	813420-82-5P	813420-83-6P
	813420-85-8P	813420-86-9P	813420-87-0P	813420-88-1P	813420-90-5P
	813420-91-6P	813420-92-7P	813420-95-0P	813420-96-1P	813420-98-3P
	813420-99-4P	813421-00-0P	813421-01-1P	813421-02-2P	813421-03-3P
	813421-04-4P	813421-05-5P	813421-06-6P	813421-07-7P	813421-08-8P
	813421-09-9P	813421-10-2P	813421-11-3P	813421-12-4P	813421-13-5P
	813421-14-6P	813421-15-7P	813421-16-8P	813421-17-9P	813421-18-0P
	813421-19-1P	813421-20-4P	813421-21-5P	813421-22-6P	
	813421-23-7P	813421-24-8P	813421-25-9P	813421-26-0P	813421-27-1P
	813421-28-2P	813421-29-3P	813421-30-6P	813421-31-7P	813421-32-8P
	813421-33-9P	813421-34-0P	813421-35-1P	813421-36-2P	813421-37-3P
	813421-38-4P	813421-39-5P	813421-40-8P	813421-41-9P	813421-42-0P
	813421-43-1P	813421-44-2P	813421-45-3P	813421-46-4P	813421-47-5P
	813421-48-6P	813421-49-7P	813421-50-0P	813421-51-1P	813421-52-2P
	813421-54-4P	813421-56-6P	813421-58-8P	813421-60-2P	813421-61-3P
	813421-62-4P	813421-63-5P	813421-64-6P	813421-65-7P	813421-66-8P
	813421-67-9P	813421-68-0P	813421-69-1P	813421-70-4P	813421-71-5P
	813421-72-6P	813421-73-7P	813421-74-8P	813421-75-9P	813421-76-0P
	813421-77-1P	813421-78-2P	813421-79-3P	813421-80-6P	813421-81-7P
	813421-82-8P	813421-84-0P	813421-85-1P, 2-[(4-Methyl-1,3'-bipiperidin-1'-yl)methyl]-N-(2-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)biphenyl-4-carboxamide	813421-86-2P	813421-87-3P,
			2-[[Ethyl(2-hydroxy-2-methylpropyl)amino]methyl]-N-(2-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)biphenyl-4-carboxamide	813421-88-4P	
	813421-89-5P	813421-90-8P	813421-91-9P	813421-93-1P	813421-95-3P
	813421-97-5P	813421-99-7P	813422-01-4P	813422-04-7P	813422-05-8P
	813422-06-9P	813422-07-0P	813422-08-1P	813422-09-2P	813422-11-6P
	813422-12-7P	813422-14-9P	813422-15-0P	813422-16-1P	813422-17-2P
	813422-18-3P	813422-19-4P	813422-20-7P	813422-21-8P	813422-22-9P
	813422-23-0P	813422-24-1P	813422-25-2P	813422-26-3P	813422-27-4P

813422-28-5P	813422-29-6P	813422-30-9P	813422-31-0P	813422-32-1P
813422-34-3P	813422-35-4P	813422-36-5P	813422-37-6P	813422-38-7P
813422-39-8P	813422-40-1P	813422-41-2P	813422-42-3P	813422-44-5P
813422-45-6P	813422-46-7P	813422-47-8P	813422-48-9P	813422-50-3P
813422-51-4P	813422-52-5P	813422-53-6P	813422-54-7P	813422-55-8P
813422-56-9P	813422-57-0P	813422-58-1P	813422-59-2P	813422-61-6P
813422-63-8P	813422-65-0P	813422-66-1P	813422-67-2P	813422-68-3P
813422-69-4P	813422-70-7P	813422-71-8P	813422-72-9P	813422-74-1P
813422-75-2P	813422-76-3P	813422-78-5P	813422-79-6P	813422-80-9P
813422-81-0P	813422-82-1P	813422-83-2P	813422-84-3P	813422-85-4P
813422-86-5P	813422-87-6P	813422-88-7P	813422-89-8P	813422-90-1P
813422-91-2P	813422-92-3P	813422-93-4P	813422-94-5P	813422-95-6P
813422-96-7P	813422-97-8P	813422-98-9P	813422-99-0P	813423-00-6P
813423-01-7P	813423-02-8P	813423-03-9P	813423-04-0P	813423-05-1P
813423-06-2P	813423-07-3P	813423-08-4P	813423-09-5P	813423-10-8P
813423-11-9P	813423-12-0P	813423-13-1P	813423-14-2P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzamide derivs. as capsaicin receptor VR1 activation inhibitors for treatment of pains)

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:515474 HCAPLUS Full-text

DOCUMENT NUMBER: 141:71359

TITLE: Preparation of tetrahydronaphthalene derivatives as vaniloid receptor antagonists

INVENTOR(S): Tajimi, Masaomi; Kokubo, Toshio; Shiroo, Masahiro; Tsukimi, Yasuhiro; Yura, Takeshi; Urbahns, Klaus; Yamamoto, Noriyuki; Mogi, Muneto; Fujishima, Hiroshi; Masuda, Tsutomu; Yoshida, Nagahiro; Moriwaki, Toshiya

PATENT ASSIGNEE(S): Bayer Healthcare Ag, Germany

SOURCE: PCT Int. Appl., 81 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052846	A1	20040624	WO 2003-EP13453	20031128
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2508618	A1	20040624	CA 2003-2508618	20031128
AU 2003294748	A1	20040630	AU 2003-294748	20031128
EP 1569896	A1	20050907	EP 2003-785688	20031128
EP 1569896	B1	20070815		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			


10/537482

JP 2006509018	T	20060316	JP 2004-557951	20031128
AT 370118	T	20070915	AT 2003-785688	20031128
US 2006128704	A1	20060615	US 2005-537482	20051118
PRIORITY APPLN. INFO.:			EP 2002-27523	A 20021206
			WO 2003-EP13453	W 20031128

OTHER SOURCE(S): MARPAT 141:71359

ED Entered STN: 27 Jun 2004

GI



AB The title compds. I [R1 = H, alkyl; X = biphenyl, etc.] are prepared The tetrahydronaphthalene derivs. of the present invention have excellent activity as VR1 antagonists and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, etc. The bioactivity of I was demonstrated.

IT 711015-38-2P 711015-39-3P 711015-40-6P
 711015-41-7P 711015-43-9P 711015-44-0P
 711015-45-1P 711015-46-2P 711015-47-3P
 711015-48-4P 711015-49-5P 711015-50-8P
 711015-51-9P 711015-52-0P 711015-53-1P
 711015-54-2P 711015-55-3P 711015-56-4P
 711015-57-5P 711015-58-6P 711015-59-7P
 711015-60-0P 711015-61-1P 711015-62-2P
 711015-63-3P 711015-64-4P 711015-65-5P
 711015-66-6P 711015-67-7P 711015-68-8P
 711015-69-9P 711015-70-2P 711015-71-3P
 711015-72-4P 711015-73-5P 711015-74-6P
 711015-75-7P 711015-76-8P 711015-77-9P
 711015-78-0P 711015-79-1P 711015-80-4P
 711015-81-5P 711015-82-6P 711015-83-7P
 711015-84-8P 711015-85-9P 711015-86-0P
 711015-87-1P 711015-88-2P 711015-89-3P
 711015-90-6P 711015-91-7P 711015-92-8P
 711015-93-9P 711015-94-0P 711015-95-1P
 711015-96-2P 711015-97-3P 711015-98-4P
 711015-99-5P 711016-00-1P 711016-01-2P
 711016-02-3P 711016-03-4P 711016-04-5P
 711016-05-6P 711016-06-7P 711016-07-8P
 711016-08-9P 711016-09-0P 711016-10-3P
 711016-11-4P 711016-12-5P 711016-14-7P
 711016-15-8P 711016-16-9P 711016-17-0P
 711016-18-1P 711016-19-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tetrahydronaphthalene derivs. as vanilloid receptor antagonists)

10/537482


RN 711015-38-2 HCAPLUS

CN Urea, N-(4'-methyl[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-39-3 HCAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 711015-40-6 HCAPLUS


CN Urea, N-(4'-chloro-3'-fluoro[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-41-7 HCAPLUS


10/537482

CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]- (CA INDEX NAME)




RN 711015-43-9 HCAPLUS

CN Urea, N-(2',4'-difluoro[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-44-0 HCAPLUS


CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)



10/537482


RN 711015-45-1 HCAPLUS

CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 711015-46-2 HCAPLUS

CN Urea, N-(2'-chloro[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-47-3 HCAPLUS

CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 711015-48-4 HCAPLUS

CN Urea, N-[4'-(methylthio)[1,1'-biphenyl]-3-yl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-49-5 HCAPLUS

CN Urea, N-(3',5'-difluoro[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-50-8 HCAPLUS


CN Urea, N-(3',5'-dimethyl[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



10/537482


RN 711015-51-9 HCAPLUS

CN Urea, N-(3'-methoxy[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-52-0 HCAPLUS

CN Urea, N-(4'-methoxy[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-53-1 HCAPLUS


CN Urea, N-(2',5'-dimethoxy[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



10/537482


RN 711015-54-2 HCAPLUS

CN Urea, N-(4'-fluoro[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-55-3 HCAPLUS

CN Urea, N-(3',4'-difluoro[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-56-4 HCAPLUS


CN Urea, N-(3'-chloro[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-57-5 HCAPLUS


10/537482

CN Urea, N-(3',5'-dichloro[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-58-6 HCAPLUS

CN Urea, N-(2',3'-dichloro[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-59-7 HCAPLUS


CN Urea, N-(2',4'-dichloro[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



10/537482


RN 711015-60-0 HCAPLUS

CN Urea, N-(2',5'-dichloro[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-61-1 HCAPLUS

CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[3'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 711015-62-2 HCAPLUS


CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[3'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



10/537482


RN 711015-63-3 HCAPLUS

CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[4'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 711015-64-4 HCAPLUS

CN Urea, N-[4'-(dimethylamino)[1,1'-biphenyl]-3-yl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-65-5 HCAPLUS


CN Urea, N-(4'-acetyl[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-66-6 HCAPLUS


10/537482

CN Urea, N-(3'-nitro[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-67-7 HCAPLUS

CN Urea, N-[4'-[2-(4-morpholinyl)ethoxy][1,1'-biphenyl]-3-yl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-68-8 HCAPLUS

CN Urea, N-[[4'-(dimethylamino)[1,1'-biphenyl]-4-yl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-69-9 HCAPLUS

CN Urea, N-[(4'-methoxy[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-70-2 HCAPLUS

CN Urea, N-[(4'-methyl[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-71-3 HCAPLUS

CN Urea, N-[(3'-chloro[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-72-4 HCAPLUS

CN Urea, N-[(2',5'-dichloro[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-73-5 HCAPLUS


CN Urea, N-[(2'-methoxy[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-74-6 HCAPLUS


CN Urea, N-[(2',5'-dimethoxy[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

10/537482




RN 711015-75-7 HCAPLUS

CN Urea, N-[(2',5'-dimethyl[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-76-8 HCAPLUS

CN Urea, N-[(3'-fluoro[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-77-9 HCAPLUS


CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 711015-78-0 HCAPLUS


CN Urea, N-[(2',4'-dichloro[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

10/537482




RN 711015-79-1 HCAPLUS

CN Urea, N-[(3',4'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-80-4 HCAPLUS

CN Urea, N-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-81-5 HCAPLUS

CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'--[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 711015-82-6 HCAPLUS

CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'--[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 711015-83-7 HCAPLUS

CN Urea, N-[(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-84-8 HCAPLUS

CN Urea, N-[(4'-(4-fluorophenyl)[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-85-9 HCAPLUS

CN Urea, N-[(3',4'-dimethoxy[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-86-0 HCAPLUS

CN Urea, N-[(2'-fluoro[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-87-1 HCAPLUS

CN Urea, N-[(2',4'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-88-2 HCAPLUS

CN Urea, N-[(2',6'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-89-3 HCAPLUS

CN Urea, N-[(3',5'-dimethyl[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-90-6 HCAPLUS

CN Urea, N-[[4'-(1-methylethyl)[1,1'-biphenyl]-4-yl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-91-7 HCAPLUS

CN Urea, N-[(3',5'-dichloro[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-92-8 HCAPLUS

CN Urea, N-[(3'-nitro[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-93-9 HCAPLUS

CN Urea, N-[(4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-94-0 HCAPLUS

CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[3'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl)methyl]- (CA INDEX NAME)




RN 711015-95-1 HCAPLUS

CN Urea, N-[[4'-(dimethylamino)[1,1'-biphenyl]-3-yl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-96-2 HCAPLUS

CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[4'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]methyl]- (CA INDEX NAME)




RN 711015-97-3 HCAPLUS

CN Urea, N-[[3',5'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-98-4 HCAPLUS

CN Urea, N-[(2',5'-dimethoxy[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711015-99-5 HCAPLUS

CN Urea, N-[(2'-methoxy[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711016-00-1 HCAPLUS

CN Urea, N-[(3',4'-dimethoxy[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711016-01-2 HCAPLUS

CN Urea, N-[(3'-nitro[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711016-02-3 HCAPLUS


CN Urea, N-[(2',4'-difluoro[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711016-03-4 HCAPLUS


10/537482

CN Urea, N-[(3',4'-difluoro[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711016-04-5 HCAPLUS

CN Urea, N-[(2'-fluoro[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711016-05-6 HCAPLUS

CN Urea, N-[(3',5'-dimethyl[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711016-06-7 HCAPLUS

CN Urea, N-[[4'-(methylthio)[1,1'-biphenyl]-3-yl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711016-07-8 HCAPLUS

CN Urea, N-[(2',6'-difluoro[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711016-08-9 HCAPLUS

CN Urea, N-[[4'-(1-methylethyl)[1,1'-biphenyl]-3-yl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711016-09-0 HCAPLUS

CN Urea, N-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711016-10-3 HCAPLUS


CN Urea, N-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711016-11-4 HCAPLUS


10/537482

CN Urea, N-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711016-12-5 HCAPLUS

CN Urea, N-[[4'-(methylsulfinyl)[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711016-14-7 HCAPLUS

CN Urea, N-[[4'-(methylthio)-6-(1-piperidinyl)[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711016-15-8 HCAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 3',4'-difluoro-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711016-16-9 HCAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 4'-(dimethylamino)-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711016-17-0 HCAPLUS

CN [1,1'-Biphenyl]-3-carboxamide, 4'-methoxy-N-methyl-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 711016-18-1 HCAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711016-19-2 HCAPLUS

CN [1,1'-Biphenyl]-3-carboxamide, 4'-phenyl-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



IC ICM C07C275-32
 ICS C07C275-42; C07C323-44; C07C275-40; C07C275-38; C07D295-08;
 C07C317-32; C07D295-12; C07C233-75; C07C237-40; C07C235-42;
 A61K031-16; A61P013-00; A61P029-00

CC 25-24 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
 Section cross-reference(s): 1

IT 711015-38-2P 711015-39-3P 711015-40-6P
 711015-41-7P 711015-43-9P 711015-44-0P
 711015-45-1P 711015-46-2P 711015-47-3P
 711015-48-4P 711015-49-5P 711015-50-8P
 711015-51-9P 711015-52-0P 711015-53-1P
 711015-54-2P 711015-55-3P 711015-56-4P
 711015-57-5P 711015-58-6P 711015-59-7P
 711015-60-0P 711015-61-1P 711015-62-2P
 711015-63-3P 711015-64-4P 711015-65-5P
 711015-66-6P 711015-67-7P 711015-68-8P
 711015-69-9P 711015-70-2P 711015-71-3P
 711015-72-4P 711015-73-5P 711015-74-6P
 711015-75-7P 711015-76-8P 711015-77-9P
 711015-78-0P 711015-79-1P 711015-80-4P
 711015-81-5P 711015-82-6P 711015-83-7P
 711015-84-8P 711015-85-9P 711015-86-0P
 711015-87-1P 711015-88-2P 711015-89-3P
 711015-90-6P 711015-91-7P 711015-92-8P
 711015-93-9P 711015-94-0P 711015-95-1P
 711015-96-2P 711015-97-3P 711015-98-4P
 711015-99-5P 711016-00-1P 711016-01-2P
 711016-02-3P 711016-03-4P 711016-04-5P
 711016-05-6P 711016-06-7P 711016-07-8P
 711016-08-9P 711016-09-0P 711016-10-3P
 711016-11-4P 711016-12-5P 711016-13-6P
 711016-14-7P 711016-15-8P 711016-16-9P
 711016-17-0P 711016-18-1P 711016-19-2P
 711016-20-5P 711016-21-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of tetrahydronaphthalene derivs. as vanilloid receptor
 antagonists)

L9 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:133223 HCAPLUS Full-text
 DOCUMENT NUMBER: 138:169972
 TITLE: Preparation of substituted N-naphthyl-N'-phenylureas
 and N-substituted naphthylacetamides as vanilloid
 receptor 1 (VR1) antagonists
 INVENTOR(S): Yura, Takeshi; Mogi, Munet; Ikegami, Yuka; Masuda,

Tsutoma; Kokubo, Toshio; Urbahns, Klaus; Lowinger, Timothy B.; Yoshida, Nagahiro; Freitag, Joachim; Meier, Heinrich; Wittka-Nopper, Reilinde; Marumo, Makiko; Shiroo, Masahiro; Tajimi, Masaomi; Takeshita, Keisuke; Moriwaki, Toshuda; Tsukimi, Yasuhiro

PATENT ASSIGNEE(S):

Bayer AG, Germany

SOURCE:

PCT Int. Appl., 186 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003014064	A1	20030220	WO 2002-EP8493	20020731
WO 2003014064	A8	20031127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2003055209	A	20030226	JP 2001-232503	20010731
CA 2455754	A1	20030220	CA 2002-2455754	20020731
AU 2002325381	A1	20030224	AU 2002-325381	20020731
EP 1414788	A1	20040506	EP 2002-758413	20020731
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005501873	T	20050120	JP 2003-524319	20020731
US 2004259875	A1	20041223	US 2004-485481	20040726
PRIORITY APPLN. INFO.:			JP 2001-232503	A 20010731
			JP 2001-392310	A 20011225
			WO 2002-EP8493	W 20020731

OTHER SOURCE(S): MARPAT 138:169972

ED Entered STN: 21 Feb 2003

GI



I

AB The title compds. R7Q(Y)C(O)NXR6 [X = (un)substituted Ph, cycloalkyl optionally fused by benzene, thienyl, quinolyl, etc.; Q = CH, N; R6, R7 = H, Me; Y = substituted 1-naphthyl] or their salts which have vanilloid receptor 1 (VR1) antagonistic activity, and therefore are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischemia, neurodegeneration, stroke, incontinence and/or inflammatory disorders, were prepared Thus, reacting 8-amino-5,7-dichloro-2-naphthol (preparation given) with 3-chlorophenyl isocyanate in 1,4-dioxane afforded 39% I which showed IC50 of ≤ 10 nM for VR1.


IT 497149-47-0P 497150-13-7P 497150-15-9P
 497150-16-0P 497150-17-1P 497150-18-2P
 497150-19-3P 497150-35-3P 497150-36-4P
 497150-42-2P 497150-43-3P 497150-44-4P
 497150-46-6P 497150-47-7P 497150-54-6P
 497150-55-7P 497150-56-8P 497150-83-1P
 497150-94-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted N-naphthyl-N'-phenylureas and N-substituted naphthylacetamides as vanilloid receptor 1 (VR1) antagonists)


RN 497149-47-0 HCAPLUS

CN Urea, N-[1,1'-biphenyl]-2-yl-N'-(7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 497150-13-7 HCAPLUS

CN Urea, N-[1,1'-biphenyl]-3-yl-N'-(2-chloro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 497150-15-9 HCAPLUS

CN Urea, N-[7-(acetyloxy)-2,4-dichloro-1-naphthalenyl]-N'-(2'-chloro[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 497150-16-0 HCAPLUS

CN Urea, N-[7-(acetyloxy)-2,4-dibromo-1-naphthalenyl]-N'-[1,1'-biphenyl]-3-yl- (CA INDEX NAME)




RN 497150-17-1 HCAPLUS

CN Urea, N-[7-(acetyloxy)-2,4-dichloro-1-naphthalenyl]-N'-(3'-methoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 497150-18-2 HCAPLUS

CN Urea, N-[7-(acetyloxy)-2,4-dichloro-1-naphthalenyl]-N'-(3'-chloro-4'-methoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 497150-19-3 HCAPLUS

CN Urea, N-[7-(acetyloxy)-2,4-dichloro-1-naphthalenyl]-N'-(4'-chloro-3'-fluoro[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 497150-35-3 HCAPLUS

CN Urea, N-(2'-chloro[1,1'-biphenyl]-3-yl)-N'-(2,4-dichloro-7-hydroxy-1-


10/537482

naphthalenyl)-, monopotassium salt (9CI) (CA INDEX NAME)




RN 497150-36-4 HCAPLUS

CN Urea, N-(2'-chloro[1,1'-biphenyl]-3-yl)-N'-(2,4-dichloro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 497150-42-2 HCAPLUS


CN Urea, N-(2,4-dichloro-7-hydroxy-1-naphthalenyl)-N'-(3'-methoxy[1,1'-biphenyl]-3-yl)-, monopotassium salt (9CI) (CA INDEX NAME)



● K

RN 497150-43-3 HCAPLUS


CN Urea, N-(3'-chloro-4'-methoxy[1,1'-biphenyl]-3-yl)-N'-(2,4-dichloro-7-hydroxy-1-naphthalenyl)-, monopotassium salt (9CI) (CA INDEX NAME)



● K

RN 497150-44-4 HCAPLUS


CN Urea, N-(4'-chloro-3'-fluoro[1,1'-biphenyl]-3-yl)-N'-(2,4-dichloro-7-hydroxy-1-naphthalenyl)-, monopotassium salt (9CI) (CA INDEX NAME)



● K


RN 497150-46-6 HCAPLUS

CN Urea, N-(4'-acetyl[1,1'-biphenyl]-3-yl)-N'-(2,4-dichloro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 497150-47-7 HCAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-[[[(2,4-dichloro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]- (CA INDEX NAME)




RN 497150-54-6 HCAPLUS

CN Urea, N-(2,4-dichloro-7-hydroxy-1-naphthalenyl)-N'-(3'-methoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 497150-55-7 HCAPLUS

CN Urea, N-(3'-chloro-4'-methyl[1,1'-biphenyl]-3-yl)-N'-(2,4-dichloro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 497150-56-8 HCAPLUS

CN Urea, N-(4'-chloro-3'-fluoro[1,1'-biphenyl]-3-yl)-N'-(2,4-dichloro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)




RN 497150-83-1 HCAPLUS

CN Urea, N-(4'-chloro[1,1'-biphenyl]-3-yl)-N'-(2,4-dichloro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 497150-94-4 HCAPLUS

CN Urea, N-[1,1'-biphenyl]-3-yl-N'-(7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



IC ICM C07C235-38

ICS C07C275-32; C07C275-34; C07C275-36; C07C275-38; C07C275-40;
 C07C275-42; C07C311-08; C07C311-47; C07C323-44; C07D209-88;
 C07D215-38; C07D235-10; C07D239-69; C07D261-14; C07D261-16;
 C07D263-10; C07D285-06; C07D295-135; C07D307-88

CC 25-24 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
 Section cross-reference(s): 1

IT	199584-96-8P	199929-52-7P	391937-38-5P	497148-29-5P	497148-30-8P
	497148-31-9P	497148-32-0P	497148-33-1P	497148-34-2P	497148-35-3P
	497148-36-4P	497148-37-5P	497148-38-6P	497148-39-7P	497148-40-0P
	497148-41-1P	497148-42-2P	497148-43-3P	497148-44-4P	497148-45-5P
	497148-46-6P	497148-47-7P	497148-48-8P	497148-49-9P	497148-50-2P
	497148-51-3P	497148-52-4P	497148-53-5P	497148-54-6P	497148-55-7P
	497148-56-8P	497148-57-9P	497148-58-0P	497148-59-1P	497148-60-4P
	497148-61-5P	497148-62-6P	497148-63-7P	497148-64-8P	497148-65-9P
	497148-66-0P	497148-67-1P	497148-68-2P	497148-69-3P	497148-70-6P
	497148-71-7P	497148-72-8P	497148-73-9P	497148-74-0P	497148-75-1P

10/537482

497148-76-2P	497148-79-5P	497148-82-0P	497148-84-2P	497148-85-3P
497148-86-4P	497148-87-5P	497148-88-6P	497148-90-0P	497148-91-1P
497148-92-2P	497148-93-3P	497148-94-4P	497148-95-5P	497148-96-6P
497148-97-7P	497148-98-8P	497149-00-5P	497149-01-6P	497149-02-7P
497149-04-9P	497149-05-0P	497149-06-1P	497149-07-2P	497149-08-3P
497149-09-4P	497149-11-8P	497149-12-9P	497149-14-1P	497149-15-2P
497149-16-3P	497149-17-4P	497149-18-5P	497149-19-6P	497149-20-9P
497149-21-0P	497149-22-1P	497149-24-3P	497149-25-4P	497149-26-5P
497149-27-6P	497149-28-7P	497149-29-8P	497149-30-1P	497149-31-2P
497149-32-3P	497149-33-4P	497149-34-5P	497149-35-6P	497149-36-7P
497149-37-8P	497149-38-9P	497149-39-0P	497149-40-3P	497149-41-4P
497149-42-5P	497149-43-6P	497149-44-7P	497149-45-8P	497149-46-9P
497149-47-0P	497149-48-1P	497149-49-2P	497149-50-5P	
497149-51-6P	497149-52-7P	497149-53-8P	497149-54-9P	497149-55-0P
497149-56-1P	497149-57-2P	497149-58-3P	497149-59-4P	497149-60-7P
497149-61-8P	497149-62-9P	497149-63-0P	497149-64-1P	497149-66-3P
497149-67-4P	497149-68-5P	497149-69-6P	497149-70-9P	497149-71-0P
497149-72-1P	497149-73-2P	497149-74-3P	497149-75-4P	497149-76-5P
497149-77-6P	497149-78-7P	497149-79-8P	497149-80-1P	497149-81-2P
497149-82-3P	497149-83-4P	497149-84-5P	497149-85-6P	497149-86-7P
497149-87-8P	497149-88-9P	497149-89-0P	497149-90-3P	497149-91-4P
497149-92-5P	497149-93-6P	497149-94-7P	497149-95-8P	497149-96-9P
497149-97-0P	497149-98-1P	497149-99-2P	497150-00-2P	497150-01-3P
497150-02-4P	497150-03-5P	497150-04-6P	497150-05-7P	497150-06-8P
497150-07-9P	497150-08-0P	497150-09-1P	497150-10-4P	497150-11-5P
497150-12-6P	497150-13-7P	497150-14-8P	497150-15-9P	
497150-16-0P	497150-17-1P	497150-18-2P		
497150-19-3P	497150-20-6P	497150-21-7P	497150-22-8P	
497150-23-9P	497150-24-0P	497150-25-1P	497150-26-2P	497150-27-3P
497150-28-4P	497150-29-5P	497150-30-8P	497150-31-9P	497150-34-2P
497150-35-3P	497150-36-4P	497150-38-6P	497150-40-0P	
497150-42-2P	497150-43-3P	497150-44-4P		
497150-45-5P	497150-46-6P	497150-47-7P	497150-48-8P	
497150-49-9P	497150-50-2P	497150-52-4P	497150-54-6P	
497150-55-7P	497150-56-8P	497150-57-9P	497150-58-0P	
497150-59-1P	497150-60-4P	497150-61-5P	497150-62-6P	497150-63-7P
497150-64-8P	497150-65-9P	497150-66-0P	497150-67-1P	497150-68-2P
497150-69-3P	497150-70-6P	497150-71-7P	497150-72-8P	497150-73-9P
497150-74-0P	497150-75-1P	497150-76-2P	497150-77-3P	497150-78-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted N-naphthyl-N'-phenylureas and N-substituted naphthylacetamides as vanilloid receptor 1 (VR1) antagonists)

IT	497150-79-5P	497150-80-8P	497150-81-9P	497150-82-0P	
	497150-83-1P	497150-84-2P	497150-85-3P	497150-86-4P	
	497150-87-5P	497150-88-6P	497150-89-7P	497150-90-0P	497150-91-1P
	497150-92-2P	497150-93-3P	497150-94-4P	497150-95-5P	
	497150-96-6P	497150-97-7P	497150-98-8P	497150-99-9P	497151-00-5P
	497151-01-6P	497151-02-7P	497151-03-8P	497151-04-9P	497151-05-0P
	497151-06-1P	497151-07-2P	497151-08-3P	497151-09-4P	497151-10-7P
	497151-11-8P	497151-12-9P	497151-13-0P	497151-14-1P	497151-15-2P
	497151-16-3P	497151-17-4P	497151-18-5P	497151-19-6P	497151-20-9P
	497151-21-0P	497151-22-1P	497151-24-3P	497151-26-5P	497151-27-6P
	497151-29-8P	497151-30-1P	497151-31-2P	497151-32-3P	497151-33-4P
	497151-34-5P	497151-35-6P	497151-36-7P	497151-37-8P	497151-38-9P
	497151-39-0P	497151-40-3P	497151-41-4P	497151-42-5P	497151-79-8P
	497155-47-2P				

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


(Uses)

(preparation of substituted N-naphthyl-N'-phenylureas and N-substituted naphthylacetamides as vanilloid receptor 1 (VR1) antagonists)


REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1992:592072 HCAPLUS Full-text
 DOCUMENT NUMBER: 117:192072
 TITLE: Preparation of naphthol phosphates for detection of nucleic acids
 INVENTOR(S): Fujita, Satoshi; Kagiya, Naoto; Momiyama, Masayoshi
 PATENT ASSIGNEE(S): Aisin Seiki K. K., Japan
 SOURCE: Brit. UK Pat. Appl., 19 pp.
 CODEN: BAXXDU
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2250991	A	19920624	GB 1991-27232	19911223
GB 2250991	B	19940810		
JP 04222600	A	19920812	JP 1990-413201	19901221
US 5484700	A	19960116	US 1991-806189	19911213
DE 4142076	A1	19920709	DE 1991-4142076	19911219
DE 4142076	C2	19960328		
PRIORITY APPLN. INFO.:			JP 1990-413201	A 19901221
OTHER SOURCE(S):		MARPAT 117:192072		
ED Entered STN:		15 Nov 1992		
GI				



I



II


AB Title compds. [I; one of R1 - R3 = A, the others = H, halo, alkyl, alkoxy, PhO, aminoacetyl, cyano, alkoxy carbonyl; A = CONHR, NHCOR, CH:CHR, CO2R, C(OR4):NR; R = (substituted) alkyl, alkoxy, PhO, (hetero)aryl; R4 = alkoxy, PhO; with provisos], were prepared. Thus, 2-acetoxy-3-formylnaphthalene (preparation given) in THF was added to a mixture of 3,4-dimethylbenzyl triphenylphosphonium chloride (preparation given) and NaOEt in THF to give 25% 2-acetoxy-3-(3,4-dimethylstyryl)naphthalene. The latter was stirred with CaCO3 in EtOH to give 90% 3-(3,4-dimethylstyryl)-2-naphthol. This was treated with POCl3 in pyridine followed by ice quenching to give title compound II. II successfully detected digoxigenin-labeled DNA at the 0.4 pg level.

IT 144077-60-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, for DNA detection)

RN 144077-60-1 HCAPLUS


CN [1,1'-Biphenyl]-4-carboxamide, N-[7-(phosphonooxy)-1-naphthalenyl] - (CA INDEX NAME)




IC ICM C07F009-12
 ICS C07F009-6541; C12Q001-42; C12Q001-68
 CC 29-7 (Organometallic and Organometalloidal Compounds)
 Section cross-reference(s): 9
 IT 144077-56-5P 144077-57-6P 144077-58-7P 144077-59-8P
 144077-60-1P 144077-61-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, for DNA detection)

L9 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1979:491500 HCAPLUS Full-text
 DOCUMENT NUMBER: 91:91500
 TITLE: Anellated indole derivatives
 INVENTOR(S): Boltze, Karl Heinz; Opitz, Wolfgang; Raddatz,
 Siegfried; Seidel, Peter Rudolf; Jacobi, Haireddin;
 Dell, Hans Dieter; Schoellnhammer, Guenter
 PATENT ASSIGNEE(S): Troponwerke G.m.b.H. und Co. K.-G., Fed. Rep. Ger.
 SOURCE: Ger. Offen., 95 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2740836	A1	19790322	DE 1977-2740836	19770910
PRIORITY APPLN. INFO.:			DE 1977-2740836	A 19770910
ED Entered STN: 12 May 1984				
GI				



I



II

AB The indole derivs. I [R = (substituted) Ph or heterocyclyl; R1 = R2 = alkyl, (esterified) carboxyalkyl, (substituted) Ph; Z = bond, CH2CH2; R3R4, R4R5, or R5R6 = 5- or 6-membered ring optionally containing 1-3 S, O, and/or N atoms] and their salts were prepared for use as antiphlogistics (no data). Thus, 6,2-MeOC10H6N(NH2)COC6H4Cl-4 reacted with levulinic acid to give 80% II.


IT 70489-00-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and cyclocondensation of, with carbonyl compds., indole derivs. from)

RN 70489-00-8 HCAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 1-(7-methoxy-1-naphthalenyl)hydrazide, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IC C07D491-04; C07D498-04; C07D487-04; C07D495-04

CC 27-11 (Heterocyclic Compounds (One Hetero Atom))

IT 70488-93-6P 70488-94-7P 70488-95-8P 70488-96-9P 70488-97-0P

70488-98-1P 70488-99-2P 70489-00-8P 70489-01-9P

70489-02-0P 70489-03-1P 70489-04-2P 70489-05-3P 70489-06-4P

70489-07-5P 70489-08-6P 70489-09-7P 70489-10-0P 70507-13-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and cyclocondensation of, with carbonyl compds., indole derivs. from)

***** INVENTOR RESULTS *****

d his l36

(FILE 'HCAPLUS' ENTERED AT 16:21:29 ON 26 NOV 2007)

L36 16 S L35 NOT L9

=> d que l36

L6 105 SEA FILE=REGISTRY SUB=L3 SSS FUL L4
 L9 6 SEA FILE=HCAPLUS ABB=ON PLU=ON L6
 L10 (35) SEA FILE=HCAPLUS ABB=ON PLU=ON "TAJIMI MASAOMI"/AU
 L11 (50) SEA FILE=HCAPLUS ABB=ON PLU=ON "KOKUBO TOSHIO"/AU
 L12 (35) SEA FILE=HCAPLUS ABB=ON PLU=ON "SHIROO MASAHIRO"/AU
 L13 (33) SEA FILE=HCAPLUS ABB=ON PLU=ON ("TSUKIMI Y"/AU OR "TSUKIMI YASUHIRO"/AU)
 L14 (32) SEA FILE=HCAPLUS ABB=ON PLU=ON "YURA TAKESHI"/AU
 L15 (63) SEA FILE=HCAPLUS ABB=ON PLU=ON "URBAHNS KLAUS"/AU
 L16 (214) SEA FILE=HCAPLUS ABB=ON PLU=ON "YAMAMOTO NORIYUKI"/AU
 L17 (14) SEA FILE=HCAPLUS ABB=ON PLU=ON "MOGI MUNETO"/AU
 L18 (63) SEA FILE=HCAPLUS ABB=ON PLU=ON "FUJISHIMA HIROSHI"/AU
 L19 (99) SEA FILE=HCAPLUS ABB=ON PLU=ON "MASUDA TSUTOMU"/AU
 L20 (22) SEA FILE=HCAPLUS ABB=ON PLU=ON ("YOSHIDA NAGAHIRO"/AU OR "YOSHIDA NAGAHIRO H"/AU)
 L21 (24) SEA FILE=HCAPLUS ABB=ON PLU=ON "MORIWAKI TOSHIYA"/AU
 L22 (19) SEA FILE=HCAPLUS ABB=ON PLU=ON L10 AND ((L11 OR L12 OR L13 OR L14 OR L15 OR L16 OR L17 OR L18 OR L19 OR L20 OR L21))
 L23 (14) SEA FILE=HCAPLUS ABB=ON PLU=ON L11 AND ((L12 OR L13 OR L14 OR L15 OR L16 OR L17 OR L18 OR L19 OR L20 OR L21))
 L24 (10) SEA FILE=HCAPLUS ABB=ON PLU=ON L12 AND ((L13 OR L14 OR L15 OR L16 OR L17 OR L18 OR L19 OR L20 OR L21))
 L25 (15) SEA FILE=HCAPLUS ABB=ON PLU=ON L13 AND ((L14 OR L15 OR L16 OR L17 OR L18 OR L19 OR L20 OR L21))
 L26 (19) SEA FILE=HCAPLUS ABB=ON PLU=ON L14 AND ((L15 OR L16 OR L17 OR L18 OR L19 OR L20 OR L21))
 L27 (21) SEA FILE=HCAPLUS ABB=ON PLU=ON L15 AND ((L16 OR L17 OR L18 OR L19 OR L20 OR L21))
 L28 (9) SEA FILE=HCAPLUS ABB=ON PLU=ON L16 AND ((L17 OR L18 OR L19 OR L20 OR L21))
 L29 (11) SEA FILE=HCAPLUS ABB=ON PLU=ON L17 AND ((L18 OR L19 OR L20 OR L21))
 L30 (4) SEA FILE=HCAPLUS ABB=ON PLU=ON L18 AND ((L19 OR L20 OR L21))
 L31 (37) SEA FILE=HCAPLUS ABB=ON PLU=ON (L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30)
 L32 (1022) SEA FILE=HCAPLUS ABB=ON PLU=ON ("BAYER HEALTHCARE"/CO OR "BAYER HEALTHCARE A G"/PA OR "BAYER HEALTHCARE A G"/CS OR "BAYER HEALTHCARE A G"/CO OR "BAYER HEALTHCARE A G GERMANY"/PA OR "BAYER HEALTHCARE A G GERMANY"/CS OR "BAYER HEALTHCARE AG"/PA OR "BAYER HEALTHCARE AG"/CS OR "BAYER HEALTHCARE AG"/CO OR "BAYER HEALTHCARE AG APRATHER WEG"/CO OR "BAYER HEALTHCARE AG BAYER SCHERING PHARMA"/CO OR "BAYER HEALTHCARE AG BAYER SCHERING PHARMA GLOBAL DRUG DISCOVERY"/CO OR "BAYER HEALTHCARE AG BAYER SCHERING PHARMA GLOBAL DRUG DISCOVERY WUPPERTAL D 42096 GERMANY"/CS OR "BAYER HEALTHCARE AG COLOGNE D 50739 GERMANY"/CS OR "BAYER HEALTHCARE AG GERMANY"/PA OR "BAYER HEALTHCARE AG GERMANY"/CS)
 L33 (15) SEA FILE=HCAPLUS ABB=ON PLU=ON L32 AND L31
 L34 (9) SEA FILE=HCAPLUS ABB=ON PLU=ON L31 AND ((BLADDER? OR

UROLOG?) (W) DISORDER?)/BI

L35 17 SEA FILE=HCAPLUS ABB=ON PLU=ON L33 OR L34
 L36 16 SEA FILE=HCAPLUS ABB=ON PLU=ON L35 NOT L9

=> d l36 ibib ab 1-16

L36 ANSWER 1 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:1170872 HCAPLUS Full-text
 DOCUMENT NUMBER: 143:440424
 TITLE: Preparation of benzoxazinylurea analogs as VR1
 vanilloid receptor antagonists
 INVENTOR(S): Fujishima, Hiroshi; Mogi, Muneto;
 Yuasa, Hiroaki; Taijimi, Masaomi; Yamamoto,
 Noriyuki; Hayashi, Fumihiko; Tsukimi,
 Yasuhiro; Gupta, Jang
 PATENT ASSIGNEE(S): Bayer Healthcare AG, Germany
 SOURCE: PCT Int. Appl., 53 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005103018	A1	20051103	WO 2005-EP3632	20050407
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG CA 2563494 A1 20051103 CA 2005-2563494 20050407 EP 1740557 A1 20070110 EP 2005-716548 20050407 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR JP 2007533673 T 20071122 JP 2007-508757 20050407 PRIORITY APPLN. INFO.: EP 2004-9274 A 20040420 WO 2005-EP3632 W 20050407				

OTHER SOURCE(S): CASREACT 143:440424; MARPAT 143:440424

AB The invention is related to ureas (I), tautomers, stereoisomers, and salts thereof [wherein Y = (CH₂)_n; n = 0-4; R₁ = (un)substituted 3-8 membered (un)saturated ring; R₂ = H, (un)substituted alk(en/yn)yl, cycloalkyl, etc.; NR₁R₂ = 5-12 membered (un)substituted (un)saturated cyclic ring; R₃ = H, alk(en/yn)yl; each R₄ = independently H, nO₂, OH, SH, CN, etc.; m = 1-3; X = O, CH₂, S, NH, N-alkyl] which are useful as active ingredients of pharmaceutical preps. Compds. I have an excellent activity as VR1 antagonists. E.g., a 4-step synthesis, starting from 2-amino-4- nitrophenol, was given for urea II. Capsaicin-induced Ca²⁺ influx in the human VR1-transfected CHO cell line in the presence of II was 24 nM. I are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urol. disorder or disease, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor

overactivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischemia, neurodegeneration, stroke; and respiratory diseases and inflammatory disorders such as asthma, chronic obstructive pulmonary (or airways) disease (COPD), common cold, cough, sneeze, bronchitis including acute and chronic bronchitis, bronchiolitis, rhinitis, allergic rhinitis, vasomotor rhinitis, mucositis, sinusitis, allergy, disorders associated with exogenous irritants such as tobacco smoke, smog, high levels of atmospheric SO₂ and noxious gases in the workplace, and airways hyperreactivity, milk product intolerance, Loeffler's pneumonia, emphysema, cystic fibrosis, bronchiectasis, pulmonary fibrosis, pneumoconiosis, collagen vascular disease, granulomatous disease, laryngitis, pharyngitis, pneumonia, pleuritis, persistent asthma and chronic asthmatic bronchitis.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 2 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:547600 HCAPLUS Full-text

DOCUMENT NUMBER: 143:59848

TITLE: Preparation of aminomethyl chromane derivatives as beta-3 adrenoreceptor agonists

INVENTOR(S): Boyer, Stephen J.; Hashimoto, Kentaro; Roelle, Thomas; Sandner, Peter; Stelte-Ludwig, Beatrix; Tinel, Hanna; Henninger, Kerstin; Concepcion, Arnel; Sakurai, Osamu; Hirai, Kanako; Inoue, Tadashi; Mochizuki, Yuki; Nunami, Noriko; Taijimi, Masaomi; Yamamoto, Noriyuki; Tsukimi, Yasuhiro

PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany

SOURCE: PCT Int. Appl., 79 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005056544	A1	20050623	WO 2004-EP13677	20041202
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005222247	A1	20051006	US 2004-996230	20041123
CA 2548922	A1	20050623	CA 2004-2548922	20041202
EP 1694664	A1	20060830	EP 2004-803429	20041202
R:	DE, ES, FR, GB, IT			

PRIORITY APPLN. INFO.: EP 2003-28781 A 20031213
WO 2004-EP13677 W 20041202

OTHER SOURCE(S): MARPAT 143:59848

AB Title compds. I [R1 = H, alkyl; X = O, NR₂; R₂ = H, alkyl; Ar₁ = (un)substituted Ph, 5-14 membered heteroaryl containing 1-3 heteroatoms

selected from O, S, or N; Ar2 = (un)substituted Ph, 5-6-membered- heteroaryl containing 1-2 heteroatoms selected from O, S, or N] and their pharmaceutically acceptable salts, are prepared and disclosed as beta-3 adrenoreceptor agonists. Thus, e.g., II was prepared by etherification of tert-Bu (2S)-2-[[tert-butyl-(dimethyl)silyl]oxy]-3-phenoxypropyl{[(2R)-6-iodo-3,4-dihydro-2H-chromen-2-yl]methyl}carbamate (preparation given) with Me salicylate followed by deprotection and subsequent hydrolysis of the Me ester. The agonistic activity of I towards β 3-adrenoceptor was evaluated by measurement of cAMP production in SK-N-MC cells and it was revealed that selected compds. of the invention possessed EC50 values in the range of 14 up to 270 nM. I as beta-3 adrenoreceptor agonist should prove useful in the treatment of urol. disorders such as, but not limited to, overactive bladder and urinary incontinence. Pharmaceutical compounds comprising I are disclosed.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 3 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:429401 HCAPLUS Full-text

DOCUMENT NUMBER: 142:463618

TITLE: Preparation of 1,2,3,4-tetrahydroquinolinyurea derivatives as vanilloid receptor antagonists

INVENTOR(S): Bouchon, Axel; Diedrichs, Nicole; Hermann, Achim; Lustig, Klemens; Meier, Heinrich; Pernerstorfer, Josef; Reissmueller, Elke; Mogi, Muneto; Fujishima, Hiroshi; Tajimi, Masaomi; Yamamoto, Noriyuki

PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany

SOURCE: PCT Int. Appl., 64 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005044802	A2	20050519	WO 2004-EP12051	20041026
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2545109	A1	20050519	CA 2004-2545109	20041026
EP 1685112	A2	20060802	EP 2004-790836	20041026
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
JP 2007523888	T	20070823	JP 2006-538691	20041026
US 2007213363	A1	20070913	US 2007-578413	20070119
PRIORITY APPLN. INFO.:			EP 2003-25575	A 20031108
			WO 2004-EP12051	W 20041026

OTHER SOURCE(S): CASREACT 142:463618; MARPAT 142:463618

AB This invention relates to 1,2,3,4-tetrahydroquinolinyurea derivs. (I) and salts thereof [wherein m, p = 0-3; X = bond, O, N(R10) (wherein R10 = H, C1-6 alkyl); with the proviso that when m = 0, then X = a bond; RA = RB = H, or RA

and RB together form a carbonyl group with the carbon-atom to which they are connected; R1 = each (un)substituted aryl or heteroaryl; R2 = C1-6 alkylcarbonyl, C1-6 alkylsulfonyl, H, HO, aryl, heteroaryl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, arylsulfonyl, or heteroaryl sulfonyl, wherein said alkyl, alkenyl or alkynyl are optionally substituted] which are useful as active ingredients of pharmaceutical preps. The 1,2,3,4-tetrahydroquinolinylurea derivs. of the present invention have vanilloid receptor (VR1) antagonistic activity (no data). These compds. can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urol. diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor overactivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; pain such as chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischemia, neurodegeneration, and stroke; and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD). Thus, 5-amino-3-hydroxy-3,4-dihydroquinolin-2(1H)-one > (300 mg, 1.68 mmol) was dissolved in EtOAc and cooled to 0° and 4-trifluoromethylbenzyl isocyanate (339 mg, 1.68 mmol) was added slowly with stirring. The reaction mixture was stirred for 1 h at room temperature and the insol. product was filtered and dried in vacuo to give 16% N-(3-Hydroxy-2-oxo-1,2,3,4-tetrahydroquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea (103 mg).

L36 ANSWER 4 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:429388 HCAPLUS Full-text
 DOCUMENT NUMBER: 142:463465
 TITLE: Preparation of bicyclic amide, carbamate or urea derivatives as vanilloid receptor modulators
 INVENTOR(S): Mogi, Muneto; Fujishima, Hiroshi; Tajimi, Masaomi; Yamamoto, Noriyuki; Urbahns, Klaus; Hayashi, Fumihiko; Tsukimi, Yasuhiro; Gupta, Jang; Yuasa, Hiroaki
 PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany
 SOURCE: PCT Int. Appl., 63 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005044786	A1	20050519	WO 2004-EP12050	20041026
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2545100	A1	20050519	CA 2004-2545100	20041026
EP 1687262	A1	20060809	EP 2004-790835	20041026
R: DE, ES, FR, GB, IT				
JP 2007511479	T	20070510	JP 2006-538690	20041026

PRIORITY APPLN. INFO.:

EP 2003-25571 A 20031108
 EP 2003-27003 A 20031122
 WO 2004-EP12050 W 20041026

OTHER SOURCE(S): CASREACT 142:463465; MARPAT 142:463465

AB This invention relates to bicyclic amide, carbamate or urea derivs. of formula A-NHCO-Y-(CH₂)_m-X-(CH₂)_p-R₁ and salts thereof [A = Q₇, Q₈; wherein Q₁, Q₄ = direct bond, methylene; Q₂ = CHR₂, or CO; Q₃ = CHR₃ or CO (wherein R₂, R₃ = H, HO, C₁-6 alkoxy, C₁-6 alkanoyloxy or (un)substituted 1-6 alkyl); with the proviso that Q₁ and Q₄ can be direct bond t the same time; R₂ = R₃ ≠ H; when Q = direct nd, then R₃ = HO, C₁-6 alkoxy, or C₁-6 alkanoyloxy; Q₅ = CH or R₅ (wherein R₅ = HO, C₁-6 alkoxy, C₁-6 alkanoyloxy, or (un)substituted C₁-6 alkyl); Q₆ = CH or CR₆ (wherein R₆ = HO, C₁-6 alkoxy, C₁-6 alkanoyloxy, or (un)substituted C₁-6 alkyl); with the proviso that Q₅ ≠ Q₆ = CH; m = 0-3; p = 0, 1; X = a bond, O, NR₄ (wherein R₄ = H, C₁-6 alkyl), with the proviso that when m = 0, then X = a bond; Y = CH₂, O or NH; R₁ = each (un)substituted aryl or heteroaryl] which are useful as active ingredients of pharmaceutical prepsns. The bicyclic amide, carbamate or urea derivs. of the resent invention has vanilloid receptor (VR₁) antagonistic activity (no data). These compds. can be used for the prophylaxis and treatment of diseases associated with VR₁ activity, in particular for the treatment of urol. diseases or disorders such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor overactivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; pain such as chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischemia, neurodegeneration, and stroke; and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD). Thus, a mixture of 70.0 mg 7-amino-1,2,3,4-tetrahydronaphthalen-2-ol and 95.0 mg 4-chloro-3-trifluoromethylphenyl isocyanate in 10 mL DMF was stirred at 50° for 2 h, concentrated under reduced pressure, and purified by silica gel chromatog. to give 49.9 mg N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)urea.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 5 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:395602 HCAPLUS Full-text

DOCUMENT NUMBER: 142:442335

TITLE: Agents for regulation of human metastin recognizing receptors and use in treating urological disorders

INVENTOR(S): Yamamoto, Noriyuki; Matsumoto, Hiroko;
 Hayashi, Fumihiko; Tajimi, Masaomi

PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany

SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005040833	A1	20050506	WO 2004-EP11250	20041006
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

PRIORITY APPLN. INFO.:

EP 2003-23850

A 20031021

AB Reagents which regulate human metastin recognizing receptor and reagents which bind to human metastin recognizing receptor gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, urol. disorder or disease such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor overactivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms. In addition to the reagents a method of screening for the agents and pharmaceutical compns. containing the reagents are also claimed.

REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 6 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:395272 HCAPLUS Full-text

DOCUMENT NUMBER: 142:447019

TITLE: Preparation of tetrahydronaphthalene and urea derivatives as VR1 antagonists for the prophylaxis and treatment of diseases associated with VR1 activity, such as urological diseases, pain and inflammatory diseases

INVENTOR(S): Bouchon, Axel; Diedrichs, Nicole; Hermann, Achim;
 Lustig, Klemens; Meier, Heinrich; Pernerstorfer,
 Josef; Reissmueller, Elke; De Vry, Jean; Møgi,
 Muneto; Urbahns, Klaus; Yura,
 Takeshi; Fujishima, Hiroshi;
 Tajimi, Masaomi; Yamamoto, Noriyuki;
 Yuasa, Hiroaki; Gupta, Jang; Tsukimi, Yasuhiro
 ; Hayashi, Fumihiko

PATENT ASSIGNEE(S): Bayer Healthcare Ag, Germany

SOURCE: PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005040119	A1	20050506	WO 2004-EP10606	20040922
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2540647	A1	20050506	CA 2004-2540647	20040922
EP 1670761	A1	20060621	EP 2004-765478	20040922
R: DE, ES, FR, GB, IT				

JP 2007508255	T	20070405	JP 2006-530003	20040922
US 2007167458	A1	20070719	US 2006-574122	20061122
PRIORITY APPLN. INFO.:			EP 2003-22235	A 20031001
			EP 2003-25570	A 20031108
			WO 2004-EP10606	W 20040922

OTHER SOURCE(S): MARPAT 142:447019

AB This invention relates to title compds. of formula A-NH-CO-E (I) [wherein A = 7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl, 5,6-(un)substituted naphthalen-1-yl, indan-1-yl, etc.; E = (un)substituted piperidin-4-yl, piperazin-4-yl] and tautomeric or stereoisomers and salts thereof, which are useful as active ingredients of pharmaceutical prepsns. I have been synthesized as VR1 antagonists, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urol. disorders or diseases, pain and inflammatory disorders or diseases. Thus, acylation of ((7S)-7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)amine with 1-(2-Chloro-4-trifluoromethylphenyl)piperidine-4-carboxylic acid gave II in 28% yield. The effects of the compds. were examined in the following several assays and pharmacol. tests: measurement of capsaicin-induced Ca²⁺ influx in a human VR1-transfected CHO cell line and in primary cultured rat dorsal root ganglia neurons, resp., measurement of capsaicin-induced bladder contraction, measurement of overactive bladder in anesthetized cystitis rats, measurement of acute pain, persistent pain, neuropathic pain, inflammatory pain and diabetic neuropathic pain (only the first assay had data). II showed an IC₅₀ ≤ 0.1 μM in the first assay. Specifically disclosed applications of I include the treatment of detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor overactivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD).

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 7 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:395257 HCAPLUS Full-text

DOCUMENT NUMBER: 142:447018

TITLE: Preparation of tetrahydronaphthalene and urea derivatives as VR1 antagonists for the prophylaxis and treatment of diseases associated with VR1 activity, such as urological diseases, pain and inflammatory diseases

INVENTOR(S): Bouchon, Axel; Diedrichs, Nicole; Hermann, Achim; Lustig, Klemens; Meier, Heinrich; Pernerstorfer, Josef; Reissmueller, Elke; Mogi, Muneto; Yura, Takeshi; Fujishima, Hiroshi; Seki, Masaomi; Koriyama, Yuji; Yasoshima, Kayo; Misawa, Keiko; Tajimi, Masaomi; Yamamoto, Noriyuki; Urbahns, Klaus; Hayashi, Fumihiko; Tsukimi, Yasuhiro; Gupta, Jang

PATENT ASSIGNEE(S): Bayer Healthcare Ag, Germany

SOURCE: PCT Int. Appl., 149 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005040100	A1	20050506	WO 2004-EP11008	20041002
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2542494	A1	20050506	CA 2004-2542494	20041002
EP 1678123	A1	20060712	EP 2004-765763	20041002
R: DE, ES, FR, GB, IT				
JP 2007509846	T	20070419	JP 2006-534634	20041002
PRIORITY APPLN. INFO.:			EP 2003-23287	A 20031015
			EP 2003-23288	A 20031015
			EP 2003-25572	A 20031108
			EP 2003-25573	A 20031108
			WO 2004-EP11008	W 20041002

OTHER SOURCE(S): CASREACT 142:447018; MARPAT 142:447018

AB This invention relates to title compds. of formula A-NH-CO-E (I) [wherein A = 7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl, 5,8-dihydrotetranaphthalen-1-yl; indan-4-yl, inden-4-yl, etc.; E = cycloalkyl optionally fused by aryl, (un)substituted Ph, hetero/aryl, NH-(CH₂)_n-R₄, etc.; n = 0-6; R₄ = (un)substituted aryl] and tautomeric or stereoisomers and salts thereof, which are useful as active ingredients of pharmaceutical prepn. I have been synthesized as VR1 antagonists, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urol. disorders or diseases, pain and inflammatory disorders or diseases. Thus, reacting (6-Ethoxy-5,8-dihydronaphthalen-1-yl)amine (preparation given) with 4-Chloro-3-trifluoromethylbenzene isocyanate gave II. The effects of the compds. were examined in the following several assays and pharmacol. tests: measurement of capsaicin-induced Ca²⁺ influx in a human VR1-transfected CHO cell line and in primary cultured rat dorsal root ganglia neurons, resp., measurement of capsaicin-induced bladder contraction, measurement of overactive bladder in anesthetized cystitis rats, measurement of acute pain, persistent pain, neuropathic pain, inflammatory pain and diabetic neuropathic pain (only the 1st assay had data). II showed an IC₅₀ in the range of 0.1 to 0.6 μ M in the 1st assay. Specifically disclosed applications of I include the treatment of detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor overactivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD).

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 8 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:395089 HCAPLUS Full-text

DOCUMENT NUMBER: 142:447221

TITLE: Preparation of 5-substituted 2-((phenylmethyl)thio)-4-phenyl-4H-1,2,4-triazole derivatives as GABA-agonists for the treatment of urinary incontinence

INVENTOR(S): Bauser, Marcus; Krueger, Joachim; Meier, Heinrich;
Voehringer, Verena; Beyreuther, Bettina; Mogi,
Muneto; Marumo, Makiko; Tsuno, Naoki; Shimizu,
Haruka; Fujishima, Hiroshi; Yuasa, Hiroaki;
Hayashi, Mayumi; Umeda, Masaomi; Iwata, Atsuko
PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany
SOURCE: PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005039569	A1	20050506	WO 2004-EP11101	20041005
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2542682	A1	20050506	CA 2004-2542682	20041005
EP 1677786	A1	20060712	EP 2004-790125	20041005
R:	DE, ES, FR, GB, IT			
JP 2007509045	T	20070412	JP 2006-534642	20041005
PRIORITY APPLN. INFO.:			EP 2003-23701	A 20031018
			WO 2004-EP11101	W 20041005

OTHER SOURCE(S): CASREACT 142:447221; MARPAT 142:447221

AB Title compds. I [R1 = alkoxy, amino, alkylamino, etc.; R2 = acyl, alkyl, etc.; R3-4 = H, halo, CN, etc.; R5 = H, OH, alkoxy, etc.; R6-7 = H, morpholino, etc.; X = divalent alkyl, NH, SOO-2] are prepared For instance, 3-(3-cyclopropyl-5-thioxo-1,5-dihydro-4H-1,2,4-triazol-4-yl)benzoic acid is reacted with bromodiphenylmethane (DMF, K₂CO₃, 60°, 16 h) to give 3-(3-(benzyhydrilsulfanyl)-5-cyclopropyl[1,2,4]triazol-4-yl)benzoic acid (II). II exhibits activity in a GABA_B assay with an IC₅₀ > 0.1 µM and ≤ 0.5 µM. I are useful for the treatment of overactive bladder, urinary incontinence such as urge urinary incontinence, benign prostatic hyperplasia (BPH), chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, or nerve injury.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 9 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:817708. HCAPLUS. Full-text

DOCUMENT NUMBER: 141:314354

TITLE: Preparation of 2-Phenoxy- and 2-phenylsulfomamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders

INVENTOR(S): Li, Yingfu; Bacon, Kevin; Sugimoto, Hiromi; Fukushima, Keiko; Hashimoto, Kentaro; Marumo, Makiko; Moriwaki, Toshiya; Nunami, Noriko; Tsuno, Naoki; Urbahns, Klaus; Yoshida, Nagahiro

PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany
 SOURCE: PCT Int. Appl., 93 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004084898	A1	20041007	WO 2004-EP2496	20040311
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004224807	A1	20041007	AU 2004-224807	20040311
CA 2520225	A1	20041007	CA 2004-2520225	20040311
EP 1608374	A1	20051228	EP 2004-719389	20040311
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008682	A	20060328	BR 2004-8682	20040311
CN 1802159	A	20060712	CN 2004-80013585	20040311
JP 2006523627	T	20061019	JP 2006-504635	20040311
NO 2005004878	A	20051021	NO 2005-4878	20051021
IN 2005CN02728	A	20070608	IN 2005-CN2728	20051021
US 2007155025	A1	20070705	US 2006-550482	20061013
PRIORITY APPLN. INFO.:				
			EP 2003-6293	A 20030324
			WO 2004-EP2496	W 20040311

OTHER SOURCE(S): MARPAT 141:314354

AB Title compds. I [X = O, S; R1 = H, halo, OH, NO2, etc.; R2 = H, halo, OH, NO2, CN, alkoxy, etc.; R3 = H, halo, OH, NO2, CN, etc.; R4 = amino, etc.] are prepared For instance, 5-cyano-2-(3,5-dichlorophenoxy)-N-(2-(dimethylamino)ethyl)-N-[2-(2,5-dioxopyrrolidin-1-yl)ethyl]benzenesulfonamide is prepared in 3 steps from N,N-dimethylethane-1,2-diamine, 5-cyano-2-(3,5-dichlorophenoxy)phenylsulfonyl chloride (preparation given) and pyrrolidine. Compds. of the invention exhibit 100 fold selectivity toward the CCR3 receptor compared to CCR1, CCR5, CCR7, CCR8 and CXCR1. I are useful in the treatment of diseases associated with CCR3 activity, e.g., asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunol. disorders.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 10 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:696338 HCAPLUS Full-text

DOCUMENT NUMBER: 141:225165

TITLE: Preparation of hydroxytetrahydronaphthalenylurea derivatives as VR1 antagonists for the prophylaxis and treatment of diseases associated with VR1 activity, such as urological diseases, pain and inflammatory diseases

INVENTOR(S): Yura, Takeshi; Mogi, Muneto;
 Fujishima, Hiroshi; Urbahns, Klaus;
 Masuda, Tsutomu; Tsukimi, Yasuhiro;

Tajimi, Masaomi; Yamamoto, Noriyuki;
 Yoshida, Nagahiro; Moriwaki, Toshiya
 PATENT ASSIGNEE(S): Bayer Healthcare AG, Germany; et al.
 SOURCE: PCT Int. Appl., 57 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004072020	A1	20040826	WO 2004-EP1055	20040205
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW:				
BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2515418	A1	20040826	CA 2004-2515418	20040205
EP 1594836	A1	20051116	EP 2004-708355	20040205
EP 1594836	B1	20070919		
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006517556	T	20060727	JP 2006-501742	20040205
US 2007027187	A1	20070201	US 2004-545556	20040205
PRIORITY APPLN. INFO.:			EP 2003-2672	A 20030212
			WO 2004-EP1055	W 20040205

OTHER SOURCE(S): MARPAT 141:225165

AB This invention relates to hydroxytetrahydronaphthalenylurea derivs. of formula I, wherein A = (CH₂)_n; n is 1-6; R₁ is H or alkyl; R₂, R₃ and R₄ are independently H, halo, hydroxy, (di)alkylamino, cycloalkylamino, alkoxy carbonyl, Ph, benzyl, sulfonamide, alkanoyl(amino), (alkyl) carbamoyl, cyano(alkyl), (un)substituted alkoxy, phenoxy, or alkylthio; X is O, S, NR₅; R₅ is H, benzyl or alkyl, and tautomeric or stereoisomers and physiol. acceptable salts thereof, which are useful as active ingredients of pharmaceutical preps. The compds. have been synthesized as VR1 antagonists, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urol. disorders or diseases, pain and inflammatory disorders or diseases. Thus, urea II and its enantiomers were prepared in several steps from 8-amino-2-naphthol and 2-(4-fluorophenoxy)ethylamine. The effects of the compds. were examined in the following several assays and pharmacol. tests: measurement of capsaicin-induced Ca²⁺ influx in a human VR1-transfected CHO cell line and in primary cultured rat dorsal root ganglia neurons, resp., measurement of capsaicin-induced bladder contraction, measurement of overactive bladder in anesthetized cystitis rats, measurement of acute pain, persistent pain, neuropathic pain, inflammatory pain and diabetic neuropathic pain (only the 1st assay had data). II and its two enantiomers all showed ≤ 0.1 μM of IC₅₀ in the 1st assay. Specifically disclosed applications of I include the treatment of urinary incontinence, urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.

DOCUMENT NUMBER: 141:123557
 TITLE: Preparation of 4-phenyl-pyrimido[4,5-b]indoles as inhibitors of MKK7, MKK4 and treatment of related diseases
 INVENTOR(S): Sato, Hiroki; Inoue, Tadashi; Ly, Tai-wei; Muramatsu, Aiko; Shimazaki, Makoto; Urbahns, Klaus; Gantner, Florian; Okigami, Hiromi; Bacon, Kevin B.; Komura, Hiroshi; Yoshida, Nagahiro; Tsuno, Naoki
 PATENT ASSIGNEE(S): Bayer Healthcare Ag, Germany
 SOURCE: PCT Int. Appl., 65 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058764	A1	20040715	WO 2003-EP14194	20031213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003300522	A1	20040722	AU 2003-300522	20031213
PRIORITY APPLN. INFO.:			EP 2002-29029	A 20021227
			WO 2003-EP14194	W 20031213

OTHER SOURCE(S): MARPAT 141:123557

AB 4-Phenyl-pyrimido[4,5-b]indoles I (R1 = H, halogen, CN, N3, NO2, NH2, alkylamino, alkyl, etc., R2 = H, OH, CN, NH2, CO2H, carbamoyl, alkyl, alkoxy, alkenyl, etc.; R3 = H, halogen, OH, CN, carbamoyl, alkyl, alkoxy, alkenyl, aminoalkyl, etc.) which are useful as an active ingredient of pharmaceutical prepsns. Thus, 6-(benzyloxy)-4-chloro-9H-pyrimido[4,5-b]indole was treated with 4-methoxyphenylboronic acid, and Pd(OAc)2 to give 6-(benzyloxy)-4-(4-methoxyphenyl)-9H-pyrimido[4,5-b]indole which was deprotected using 2, and Pd(OH)2 to give 4-(4-methoxyphenyl)-9H-pyrimido[4,5-b]indol-6-ol which was an inhibitor of both MKK7 and MKK4. The 4-phenyl-pyrimido[4,5-b]indoles of the present invention have MKK7 and MKK4 inhibitory activity, and can be used for the prophylaxis and treatment of diseases associated with MKK7 and MKK4 activity. Such diseases include, inflammatory and immunoregulatory disorders and diseases such as asthma, atopic dermatitis, rhinitis, allergic rhinitis, allergic diseases, COPD, septic shock, arthritis, joint diseases and myocardial injuries, as well as autoimmune pathologies such as rheumatoid arthritis, Graves' disease, and atherosclerosis as well as cancer.

L36 ANSWER 12 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:515473 HCAPLUS Full-text

DOCUMENT NUMBER: 141:71358

TITLE: Preparation of tetrahydronaphthalene derivatives as vanilloid receptor antagonists

INVENTOR(S): Tajimi, Masaomi; Kokubo, Toshio; Shiroo, Masahiro; Tsukimi, Yasuhiro; Yura, Takeshi; Yamamoto, Noriyuki;

Mogi, Muneto; Fujishima, Hiroshi;
Masuda, Tsutomu; Yoshida, Nagahiro;
Moriwaki, Toshiya

PATENT ASSIGNEE(S): Bayer Healthcare Ag, Germany; Urbahns, Klaus

SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052845	A1	20040624	WO 2003-EP13452	20031128
WO 2004052845	A8	20050609		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2508845	A1	20040624	CA 2003-2508845	20031128
AU 2003288200	A1	20040630	AU 2003-288200	20031128
EP 1572632	A1	20050914	EP 2003-780088	20031128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006509017	T	20060316	JP 2004-557950	20031128
US 2006135505	A1	20060622	US 2005-537217	20051118
PRIORITY APPLN. INFO:			EP 2002-27528	A 20021209
			WO 2003-EP13452	W 20031128

OTHER SOURCE(S): MARPAT 141:71358

AB The title compds. I [n = 0 - 6; R1 = H, alkyl; R2 = alkenyl, alkynyl, alkyl substituted by amino, etc.; R3 = H, alkenyl, alkynyl, alkyl optionally substituted by amino, etc.; or NR2R3 = heterocyclic ring (further details on said heterocyclic ring are given); R4 = H, halo, alkylthio, alkyl optionally substituted by mono-, di-, tri-halogen, etc.] are prepared. The tetrahydronaphthalene derivs. of the present invention have excellent activity as VR1 antagonists and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, etc. The bioactivity of compds. of this invention was demonstrated.

L36 ANSWER 13 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:290454 HCAPLUS Full-text

DOCUMENT NUMBER: 140:297515

TITLE: Use of vanilloid receptor antagonists for the treatment of urological disorder

INVENTOR(S): Shiroo, Masahiro; Yura, Takeshi;
Yamamoto, Noriyuki; Tajimi, Masomi;
Tsukimi, Yasuhiro

PATENT ASSIGNEE(S): Bayer Healthcare Ag, Germany

SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028440	A2	20040408	WO 2003-EP10111	20030911
WO 2004028440	A3	20040715		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003273856	A1	20040419	AU 2003-273856	20030911
PRIORITY APPLN. INFO.:				
			EP 2002-21367	A 20020924
			WO 2003-EP10111	W 20030911
AB The invention relates to methods for treating urol. disorders. More particularly, this invention involves the use of a vanilloid receptor (VR1) antagonist for the prophylaxis and treatment of urinary incontinence and overactive bladder.				

L36 ANSWER 14 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:989726 HCAPLUS Full-text
 DOCUMENT NUMBER: 140:28043
 TITLE: Preparation of N-acylphenylalanines as prostaglandin I2 antagonists.
 INVENTOR(S): Urbahns, Klaus; Yamamoto, Noriyuki
 ; Yoshikawa, Satoru; Shimazaki, Makato; Sakurai, Osamu; Hirai, Kanako; Umeda, Masaomi; Tajimi, Masaomi
 PATENT ASSIGNEE(S): Bayer Ag, Germany
 SOURCE: Brit. UK Pat. Appl., 36 pp.
 CODEN: BAXXDU
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2389582	A	20031217	GB 2002-13598	20020613
CA 2489249	A1	20031224	CA 2003-2489249	20030612
WO 2003106403	A1	20031224	WO 2003-EP6168	20030612
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003237928	A1	20031231	AU 2003-237928	20030612

EP 1515942 A1 20050323 EP 2003-735608 20030612
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2005529181 T 20050929 JP 2004-513237 20030612
 US 2006135613 A1 20060622 US 2006-517646 20060127
 PRIORITY APPLN. INFO.: GB 2002-13598 A 20020613
 WO 2003-EP6168 W 20030612

OTHER SOURCE(S): MARPAT 140:28043

AB R1C6H4XCONH(CH2)mCHR2(CH2)nCO2H [m, n = 0-2; X = CH2CH2, CH:CH, C.tplbond.C;
 R1 = OR11, SR11, SOR11, SO2R11, NR12R13, CHR14R15; R11 = alkenyl, alkynyl,
 alkyl optionally substituted by aryl or heteroaryl; R12, R13 = H, R11; R12R13N
 = 5-7 membered saturated heterocyclyl optionally interrupted by O or NH; R14,
 R15 = H, alkenyl, alkynyl, alkyl, alkoxy optionally substituted by aryl or
 heteroaryl; R14R15CH = cycloalkyl optionally interrupted by NH or O, or
 R14R15CH = Ph optionally substituted by OH, halo, alkyl; R2 = H, cyano,
 alkoxy, alkenyl, alkynyl, cycloalkyl, or alkyl optionally substituted by
 amino, alkylamino, Ph], were prepared Thus, a mixture of tert-Bu 4-
 phenoxyethylcinnamate (preparation given), CF3CO2H, and CH2Cl2 was allowed
 to stand for 2.5 h at room temperature; solvent was removed in vacuo and the
 residue in DMF was treated with phenylalanine Me ester, 1-ethyl-3-(3-
 dimethylaminopropyl)carbodiimide, 1-hydroxybenzotriazole, and Et3N followed by
 stirring at room temperature overnight to obtain 88% N-(4-
 phenoxyethylcinnamoyl)phenylalanine Me ester. Saponification of the latter
 with LiOH in H2O/MeOH gave 86% N-(4- phenoxyethylcinnamoyl)phenylalanine.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 15 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:989723 HCAPLUS Full-text

DOCUMENT NUMBER: 140:28042

TITLE: Preparation of N-naphthoylphenylalanines as
 prostaglandin I2 antagonists

INVENTOR(S): Shimazaki, Makato; Sakurai, Osamu; Urbahns,
 Klaus; Yamamoto, Noriyuki; Yoshikawa,
 Satoru; Umeda, Masaomi; Tajimi, Masaomi

PATENT ASSIGNEE(S): Bayer Ag, Germany

SOURCE: Brit. UK Pat. Appl., 26 pp.

CODEN: BAXXDU

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2389580	A	20031217	GB 2002-13488	20020612
CA 2489286	A1	20031224	CA 2003-2489286	20030530
WO 2003106402	A1	20031224	WO 2003-EP5705	20030530
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003238180	A1	20031231	AU 2003-238180	20030530
EP 1515941	A1	20050323	EP 2003-735507	20030530

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2005529180 T 20050929 JP 2004-513236 20030530
 US 2006166989 A1 20060727 US 2005-517677 20050711
 PRIORITY APPLN. INFO.: GB 2002-13488 A 20020612
 WO 2003-EP5705 W 20030530

OTHER SOURCE(S): MARPAT 140:28042

AB Title compds. [I; m, n = 0-2; R1 = OR11, SR11, SOR11 SO2R11, NR12R13, CHR14R15; R11 = alkenyl, alkynyl alkyl optionally substituted by aryl or heteroaryl; R12, R13 H, R11; R12R13N = 5-7 membered saturated heterocyclyl interrupted by O or NH; R14, R15 H, alkenyl optionally substituted by aryl or heteroaryl, alkynyl optionally substituted by aryl or heteroaryl, alkyl optionally substituted by aryl or heteroaryl, alkoxy optionally substituted by aryl or heteroaryl; R14R15CH = cycloalkyl optionally interrupted by NH, or O, or R14R15CH = Ph optionally substituted by OH, halo or alkyl; R2 = H, cyano, alkoxy, alkenyl, alkynyl, cycloalkyl, alkyl optionally substituted by amino, alkylamino, Ph], were prepared for treatment of pain, inflammation, urol. disorders, hypotension, hemophilia, and hemorrhage (no data). Thus, 6-hydroxy-2-naphthoic acid, DL-phenylalanine Me ester, 1-hydroxybenzotriazole, Et3N, and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride were stirred overnight in DMF to give 85% N-(6-hydroxy-2-naphthoyl)phenylalanine Me ester. This was benzylated (76%) followed by saponification with LiOH in H2O/MeOH to give 82% N-(6-benzyloxy-2-naphthoyl)phenylalanine.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 16 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:837138 HCAPLUS Full-text

DOCUMENT NUMBER: 139:318465

TITLE: Sequences of human transient receptor potential channel sequence homologs and uses in diagnosis, therapy and drug screening

INVENTOR(S): Shiroo, Masahiro; Yamamoto, Noriyuki
 ; Hayashi, Fumihiko; Floeckner, Johannes; Reinemer, Peter; Encinas, Jeffrey; Watanabe, Shinichi; Tajimi, Masaomi; Kokubo, Toshio

PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany; Bayer Healthcare AG

SOURCE: PCT Int. Appl., 116 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003087158	A2	20031023	WO 2003-EP3713	20030410
WO 2003087158	A3	20040610		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003226797	A1	20031027	AU 2003-226797	20030410

10/537482

EP 1497328	A2	20050119	EP 2003-746288	20030410
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006510343	T	20060330	JP 2003-584113	20030410
US 2005176010	A1	20050811	US 2005-511556	20050428
PRIORITY APPLN. INFO.:			US 2002-372899P	P 20020416
			US 2002-375139P	P 20020422
			WO 2003-EP3713	W 20030410

AB The invention provides protein and cDNA sequences of novel human transient receptor potential channel sequence homologs. The invention also provides reagents and methods of regulating human transient receptor potential channel sequence homologs. Reagents that regulate human transient receptor potential channels and reagents which bind to human transient receptor potential channel gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including urinary incontinence, overactive bladder, benign prostatic hyperplasia, lower urinary tract syndromes, and CNS disorders.

=> d his nofile

(FILE 'HOME' ENTERED AT 16:14:49 ON 26 NOV 2007)

FILE 'REGISTRY' ENTERED AT 16:15:02 ON 26 NOV 2007

L1 STRUCTURE UPLOADED
D
L2 3 SEA SSS SAM L1
D SCAN
L3 106 SEA SSS FUL L1
L4 STRUCTURE UPLOADED
L5 6 SEA SUB=L3 SSS SAM L4
L6 105 SEA SUB=L3 SSS FUL L4
L7 1 SEA ABB=ON PLU=ON L3 NOT L6
D SCAN

FILE 'HCAPLUS' ENTERED AT 16:21:29 ON 26 NOV 2007

L8 1 SEA ABB=ON PLU=ON L7
L9 6 SEA ABB=ON PLU=ON L6

D QUE L9

D L9 IBIB ED ABS HITSTR HITIND 1-6

ACT NAG482HCAIN/A

L10 (35)SEA ABB=ON PLU=ON "TAJIMI MASAOMI"/AU
L11 (50)SEA ABB=ON PLU=ON "KOKUBO TOSHIO"/AU
L12 (35)SEA ABB=ON PLU=ON "SHIROO MASAHIRO"/AU
L13 (33)SEA ABB=ON PLU=ON ("TSUKIMI Y"/AU OR "TSUKIMI YASUHIRO"/AU)
L14 (32)SEA ABB=ON PLU=ON "YURA TAKESHI"/AU
L15 (63)SEA ABB=ON PLU=ON "URBAHNS KLAUS"/AU
L16 (214)SEA ABB=ON PLU=ON "YAMAMOTO NORIYUKI"/AU
L17 (14)SEA ABB=ON PLU=ON "MOGI MUNETO"/AU
L18 (63)SEA ABB=ON PLU=ON "FUJISHIMA HIROSHI"/AU
L19 (99)SEA ABB=ON PLU=ON "MASUDA TSUTOMU"/AU
L20 (22)SEA ABB=ON PLU=ON ("YOSHIDA NAGAHIRO"/AU OR "YOSHIDA
NAGAHIRO H"/AU)
L21 (24)SEA ABB=ON PLU=ON "MORIWAKI TOSHIYA"/AU
L22 (19)SEA ABB=ON PLU=ON L10 AND ((L11 OR L12 OR L13 OR L14 OR L15
OR L16 OR L17 OR L18 OR L19 OR L20 OR L21))
L23 (14)SEA ABB=ON PLU=ON L11 AND ((L12 OR L13 OR L14 OR L15 OR L16
OR L17 OR L18 OR L19 OR L20 OR L21))
L24 (10)SEA ABB=ON PLU=ON L12 AND ((L13 OR L14 OR L15 OR L16 OR L17
OR L18 OR L19 OR L20 OR L21))
L25 (15)SEA ABB=ON PLU=ON L13 AND ((L14 OR L15 OR L16 OR L17 OR L18
OR L19 OR L20 OR L21))
L26 (19)SEA ABB=ON PLU=ON L14 AND ((L15 OR L16 OR L17 OR L18 OR L19
OR L20 OR L21))
L27 (21)SEA ABB=ON PLU=ON L15 AND ((L16 OR L17 OR L18 OR L19 OR L20
OR L21))
L28 (9)SEA ABB=ON PLU=ON L16 AND ((L17 OR L18 OR L19 OR L20 OR
L21))
L29 (11)SEA ABB=ON PLU=ON L17 AND ((L18 OR L19 OR L20 OR L21))
L30 (4)SEA ABB=ON PLU=ON L18 AND ((L19 OR L20 OR L21))
L31 (37)SEA ABB=ON PLU=ON (L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR
L28 OR L29 OR L30)
L32 (1022)SEA ABB=ON PLU=ON ("BAYER HEALTHCARE"/CO OR "BAYER HEALTHCARE
A G"/PA OR "BAYER HEALTHCARE A G"/CS OR "BAYER HEALTHCARE A
G"/CO OR "BAYER HEALTHCARE A G GERMANY"/PA OR "BAYER HEALTHCARE
A G GERMANY"/CS OR "BAYER HEALTHCARE AG"/PA OR "BAYER

10/537482

HEALTHCARE AG"/CS OR "BAYER HEALTHCARE AG"/CO OR "BAYER
HEALTHCARE AG APRATHER WEG"/CO OR "BAYER HEALTHCARE AG BAYER
SCHERING PHARMA"/CO OR "BAYER HEALTHCARE AG BAYER SCHERING
PHARMA GLOBAL DRUG DISCOVERY"/CO OR "BAYER HEALTHCARE AG BAYER
SCHERING PHARMA GLOBAL DRUG DISCOVERY WUPPERTAL D 42096
GERMANY"/CS OR "BAYER HEALTHCARE AG COLOGNE D 50739 GERMANY"/CS
OR "BAYER HEALTHCARE AG GERMANY"/PA OR "BAYER HEALTHCARE AG
GERMANY"/CS)

L33 (15) SEA ABB=ON PLU=ON L32 AND L31
L34 (9) SEA ABB=ON PLU=ON L31 AND ((BLADDER? OR UROLOG?) (W)
DISORDER?)/BI
L35 17 SEA ABB=ON PLU=ON L33 OR L34

L36 16 SEA ABB=ON PLU=ON L35 NOT L9
D QUE L36
D L36 IBIB AB 1-16